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EC Endothelial cell  
HUVEC Human umbilical vein endothelial cell  
KD Knock-down  
MCD Methyl--cyclodextrin 
MMP Matrix metalloproteinase  
ORP OSBP-related protein  
OSBP Oxysterol-binding protein  
PI(4,5)P2 Phosphatidylinositol-4,5-bisphosphate  
PIP Phosphatidylinositol phosphate  
PM Plasma membrane  
VEGF Vascular endothelial growth factor  








Oxysterol-binding protein related protein 2 (ORP2), a cholesterolPI(4,5)P2 
countercurrent transporter, was recently identified as a novel regulator of plasma 
membrane (PM) cholesterol and PI(4,5)P2 content in HeLa cells. Here, we 
investigated the role of ORP2 in endothelial cell (EC) cholesterol and PI(4,5)P2 
distribution, angiogenic signaling and angiogenesis. We show that ORP2 knock-down 
modifies the distribution of cholesterol accessible to a D4H probe, between late 
endosomes and the PM. Depletion of ORP2 from ECs inhibits their angiogenic tube 
formation capacity, alters the gene expression of angiogenic signaling pathways such 
as VEGFR2, Akt, mTOR, eNOS and Notch, and reduces EC migration, proliferation 
and cell viability. We show that ORP2 regulates the integrity of VEGFR2 at the PM 
in a cholesterol-dependent manner, the depletion of ORP2 resulting in proteolytic 
cleavage by matrix metalloproteinases and reduced activity of VEGFR2 and its 
downstream signaling. We demonstrate that ORP2 depletion increases PM PI(4,5)P2 
coincident with altered F-actin morphology, and reduces both VEGFR2 and 
cholesterol in buoyant raft membranes. Moreover, ORP2 knock-down suppresses 
expression of the lipid raft-associated proteins VE-cadherin and caveolin-1. Analysis 
of the retinal microvasculature in ORP2 knock-out mice generated during this study 
demonstrates subtle alterations of morphology characterized by reduced vessel length 
and increased density of tip cells and perpendicular sprouts. Gene expression changes 
in the retina suggest disturbance of sterol homeostasis, down-regulation of VE-
cadherin, and a putative disturbance of Notch signaling. Our data identifies ORP2 as a 
novel regulator of EC cholesterol and PI(4,5)P2 homeostasis and cholesterol-





Cholesterol is considered an indispensable component of cellular membranes. Not 
only does it serve as a structural component and regulator of membrane biophysical 
properties, but it is also a major component of plasma membrane (PM) lipid rafts 
where it functions as a platform for multiple signaling processes (1, 2). In endothelial 
 4 
cells (ECs) cholesterol and its efficient transport have a particularly important role, 
given the function of these cells as a barrier between the circulation and the tissues, 
their abundant vectorial transport tasks, and their richness in lipid rafts including 
caveolae. Accordingly, disturbances in EC lipid order are suggested to be causative 
factors in diseases such as atherosclerosis, type 2 diabetes and cancers. Recently, PM 
cholesterol has proven to play an important role in the regulation of angiogenesis, i.e. 
in the formation of new blood vessels from pre-existing ones (3-6). However, the 
factors and detailed mechanisms linking cholesterol transport to angiogenesis remain 
poorly understood.  
Vascular endothelial growth factor (VEGF) is a major initiator of 
angiogenic signaling and vessel formation in ECs. VEGF binds to the extracellular 
domain of its major receptor, vascular endothelial growth factor receptor 2 
(VEGFR2), inducing receptor dimerization and autophosphorylation of its 
intracellular tyrosine residues leading to the activation of downstream effectors such 
as PI3K/Akt, ERK, FAK and eNOS (7). The activation of these signaling pathways 
results in increased cell viability, proliferation and migration as well as increased 
barrier permeability, functions essential for the initiation of angiogenesis. Several 
recent reports suggest that PM cholesterol and the integrity of lipid rafts are crucial 
for VEGFR2 signaling, and that perturbations of intracellular cholesterol transport 
result in impaired angiogenesis (3, 5, 6, 8).  
Oxysterol-binding protein homologs, ORPs, constitute a ubiquitously 
expressed family of lipid-binding proteins with various functions in lipid transport 
and signaling. ORPs are typically localized at membrane contact sites (MCSs), where 
they generate and maintain organelle-specific lipid compositions (9). ORP2 encoded 
by OSBPL2 has a lipid-binding cavity with affinity for oxysterols, cholesterol and 
phosphatidylinositol phosphates (PIPs). ORP2 has several documented cellular 
functions related to cholesterol homeostasis, triglyceride metabolism, cell adhesion, 
migration, proliferation (10-14) and steroid hormone synthesis in adrenocortical cells 
(15). ORP2 targets lipid droplet-endoplasmic reticulum MCSs, late endosomes (LE) 
and the plasma membrane (PM) where it co-localizes with lamellipodial F-actin and 
induces PM protrusions. Recently ORP2 was proposed by us and others (16, 17) to 
regulate the intracellular transport of cholesterol to the PM by transferring cholesterol 
in exchange for PI(4,5)P2 and thus controlling the PM lipid composition.  
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In the present work we assess the role of ORP2 in EC cholesterol 
trafficking and angiogenesis in vitro and in vivo. We show that the knock-down (KD) 
of ORP2 accumulates D4H-accessible cholesterol in LEs reducing its distribution to 
the PM, reduces cholesterol in a buoyant raft fraction, and causes disturbances in 
angiogenic signaling. We identify ORP2 as a novel regulator of VEGFR2 signaling 
and show that ORP2 KD causes VEGFR2 cleavage at the PM of ECs and inhibits the 
activity of the receptor and its downstream targets upon VEGF stimulus. ORP2 KO 
mice present with a subtle alteration of retinal angiogenesis, supporting the relevance 
of the observations in vivo. 
 
 
MATERIALS AND METHODS 
 
Antibodies and reagents 
The primary antibodies used are specified in Supplementary Table S1. The secondary 
fAlexa Fluor-488 anti-mouse IgG was from Molecular Probes/Invitrogen (Carlsbad, 
CA), Cy5
®
 anti-rabbit from Life Technologies (Eugene, OR) and Oregon Green® 488 
Phalloidin from Thermo Scientific (Waltham, MA).  
The Strep-Tactin
®
 XT magnetic beads were purchased from IBA Lifesciences 
(Goettingen, DE), NeutrAvidin agarose beads from Thermo Scientific, and Protein G 
Magnetic beads from Pierce/Thermo Scientific. The Sulfo-NHS-SS-Biotin for cell 
surface receptor biotinylation was purchased from Thermo Scientific and the matrix 
metalloproteinase (MMP) inhibitor Marimastat from Sigma-Aldrich (Saint Louis, 
MO). The Silencer Select
®
 OSBPL2 and the Negative Control #2 siRNA were from 
Ambion/Thermo Scientific (Austin, TX). Puromycin was purchased from 
Gibco/Fisher Scientific (Loughborough, UK), in vitro Angiogenesis assay kit 









A), sterol-binding deficient (ELSK; deletion of E87-K90) mutants in pmCherry-
C1 (Clontech/Takara Bio) were described in (18), and GFP-tagged versions of these 
mutants were generated by transferring the cDNAs into BglII/KpnI restriction sites of 
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the pEGFP-C1 vector (Clontech/Takara Bio). The mCherry-D4H cholesterol probe 
plasmid was a kind gift from Prof. Gregory Fairn (Department of Biochemistry, 
University of Toronto, ON).  
 
Generation of ORP2 shRNA expressing lentiviruses  
The generation of a lentiviral ORP2-2xStrep expression construct is described in (16). 
The ORP2 knock-down lentiviruses were generated by using shRNA clones 
TRCN000154381 and TRCN0000429830 in pLKO.1 (Sigma-Aldrich). The non-
target shRNA control lentivirus was generated from SHC002 (Sigma-Aldrich) and the 
overexpression control lentivirus from an empty pENTR2b vector recombined with 
pLenti6.3/V5-DEST (Invitrogen). The lentiviruses were packaged by the Biomedicum 
Functional Genomics Unit (the HiLIFE Institute, Helsinki, Finland). 
 
Addressing possible shRNA off-target effects 
The possible off-target effects of ORP2 shRNA were addressed by conducting all of 
the ORP2 gene silencing experiments (excluding the next generation RNA 
sequencing) with two independent shRNAs: TRCN000154381 and TRCN000429830. 
The next generation RNA sequencing was performed on HUVEC shORP2 samples 
silenced with TRCN000154381, and the putative off-target genes of the RNA 
sequencing results, i.e. the genes where a seed sequence identical to the used shRNA 
was found, were excluded from the data before further analysis by using the GESS 
algorithm (19). 
 
Cell culture and genetic manipulations 
Human umbilical vein endothelial cells (HUVECs), the EC growth medium 
Endothelial Cell Growth Medium v2 (ECGM2) and the ECGM2 Supplement Mix 
were purchased from PromoCell (Heidelberg, DE). The cells were grown in 
Fibronectin 10 µg/ml - gelatin 0.05% (Sigma-Aldrich) coated flasks/plates in a 37°C 
humidified incubator. For cDNA transfections by electroporation, the Nucleofector
TM
 
Kit (Lonza, Basel, CH) for HUVECs was used according to Amaxa
TM
 Optimized 
Protocol. For lentivirus-mediated transductions, HUVECs were incubated for 48 h 
with either fresh or concentrated lentiviruses using a multiplicity of infection (MOI) 
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of 10, followed by 24-h antibiotic selection with 2.5 µg/ml puromycin for lentivirus-
mediated shRNA silencing.  
 
Fluorescence microscopy  
The fluorescent labels were visualized with a Zeiss Axio Observer Z1 microscope 
equipped with PInApo x63/1.40 oil DICII objective and a Colibri LED light source 
(Zeiss, Oberkochen, DE). Images were taken with an AxioCam HRm camera and 
recorded with Zen 2 v.2.0.0 software (Zeiss). Adobe Photoshop CC 2017 (Adobe, San 
Jose, CA) and Image J/Fiji (National Institutes of Health, Bethesda, MD) were used 
for image processing and analysis.  
 
Preparation of PI(4,5)P2 sensor  
The PI(4,5)P2 sensor was prepared from the engineered epsin 1 ENTH domain as 
described previously (20). Briefly, the engineered epsin 1 ENTH domain was 
expressed as a glutathione-S-transferase (GST)-tagged protein in E. coli BL21 RIL 
codon plus (Stratagene, San Diego, CA) cells and purified using the GST–affinity 
resin (GenScript, Piscataway, NJ). The purified protein was labeled at a single Cys 
with acrylodan to generate a ratiometric sensor. The sensor was calibrated using giant 
unilamellar vesicles with the lipid composition stipulating that of the inner leaflet of 
the plasma membranes of mammalian cells (20-22).   
 
Measurement of plasma membrane PI(4,5)P2 content 
HUVECs were seeded (5 x 10
4
 cells) into 50-mm round glass–bottom plates (MatTek, 
Ashland, MA) and grown in 2 ml of ECGM2 (PromoCell) supplemented with 
ECGM2 Supplement Mix (PromoCell) at 37
o
C in a humidified atmosphere with 5% 
CO2. Cells were transfected with the freshly packaged lentivirus encoding ORP2 or 
control shRNA (100 µl) using 1.1 µl of polybrene (10 μg/ml) and allowed to grow for 
48 hours, followed by treatment with puromycin (2.5 µg/ml) for 24 hours. The 
PI(4,5)P2 sensor was delivered into the cells by microinjection and PI(4,5)P2 in the 
inner leaflets of the plasma membrane (PM) was quantified using a custom-modified 
Olympus FV3000 confocal microscope as described previously (20). All data 
acquisition and ratiometric imaging data analyses were performed as described in (20-
22). The PI(4,5)P2 concentration at the PM of a single HUVEC cell was determined in 
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a spatiotemporally resolved manner and spatially averaged at a given time. Each data 
set was collected from a minimum of 15 different cells and averaged.  
The PI(4,5)P2 content was also measured from the PM of ORP2 KD and 
control HUVECs by utilizing a competitive PI(4,5)P2 ELISA Kit (Echelon 
Biosciences, Salt Lake City, UT). Approximately 20 x 10
6
 HUVECs transduced by 
either shORP2 or shCTRL virus were collected and the PM of the cells was isolated 
by Minute™ Plasma Membrane Kit (Invent Biotechnologies, Plymouth, MN) 
according to manufacturer’s protocol. The lipids of the obtained PM pellet were 
extracted according to the instructions of the PI(4,5)P2 ELISA Kit, and the PI(4,5)P2 
content of the PM lipids was determined with an EnSpire fluorometer/multimode 
plate reader (Perkin Elmer, Waltham, MA). The results were normalized to the 
cytosolic protein content of the respective cell samples (BCA assay, Pierce/Thermo 
Fisher Scientific).  
 
Measurement of plasma membrane cholesterol content 
For the PM cholesterol content measurements, the PM of ORP2 KD and control 
HUVECs was isolated by Minute™ Plasma Membrane Kit (Invent Biotechnologies, 
Plymouth, MN) as described above, and the PM cholesterol concentration was 
determined by using the Amplex Red assay (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. The results were normalized by the protein content of 
the PM samples (BCA assay, Pierce/Thermo Fisher Scientific).  
For assaying the cholesterol pool of the extracellular leaflet of the PM,  
purified His6-ALOD4 obtained as a gift from Prof. Arun Radhakrishnan (Univ. of 
Texas Southwestern Medical Center, Dallas) was used as described in (23). Briefly, 
the cells were incubated with growing concentrations (0 µM, 3 µM and 10 µM) of 
His6-ALOD4 for 1 hour at 37
o
C, rinsed with PBS and lysed. The association of the 
probe with cell surface cholesterol was analyzed from the lysates by western blot with 
anti-His6 antibody (ABclonal, Woburn, MA). 
 
EC in vitro angiogenesis assay 
In vitro angiogenesis assay (Millipore) was performed according to the 
manufacturer´s protocol. After 48-h lentivirus transduction, 1.5x10
4
 cells were seeded 
on ECM Matrix
TM
 and incubated at +37°C for 12 h. Tube formation was visualized 
under an inverted light microscope with 4x magnification and the images were 
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acquired with Evos XL Cell Imaging System (AMG; Thermo Fisher Scientific). 
Images were analyzed by using Angiogenesis Analyzer of ImageJ. 
 
RNA sequencing and analysis of differential gene expression  
For RNA sequencing sample preparation, HUVECs were transduced with shORP2 or 
control lentivirus for 48 h, followed by 24-h antibiotic selection with 2.5 µg/ml of 
Puromycin (Gibco). The RNA was isolated from cell lysates with the Qiagen 
RNeasy
TM
 Mini kit (Hilden, DE) according to the manufacturer’s protocol. Genomic 
DNA background was depleted prior to sequencing by DNAse treatment (Qiagen). 
Differential expression analysis was performed using the Chipster suite 
(24), and the following workflow was used to generate the differential expression 
data: Single-end reads were aligned to the reference genome GRCh38, with Bowtie2 
(25). Mapped reads were counted using HTseq with the ENSEMBL GRCh38 
annotation file as a reference (26). Finally, differential expression analysis was 
performed using DESeq2, with a cut-off value for Benjamini-Hochberg adjusted p-
values of 0.05 (27). Over-representation analysis of significantly differentially 
expressed genes was performed using the ConsensusPathDB web application (28), 
available at: http://ConsensusPathDBdb.org. Wikipathways, KEGG, Reactome and 
PID were selected as the most relevant databases for the pathway analysis of this 
study. 
 
Strep-Tactin pull down and ORP2 interactome analysis 
HUVECs were grown on 10 cm dishes and transduced with ORP2-2xStrep or 
overexpression control lentivirus for 48 h. Subsequently, the cells were lysed in 
freshly prepared lysis buffer [10 mM HEPES (pH 7.6), 150 mM NaCl, 0.5 mM 
MgCl2, 10% glycerol, 0.5% Triton X-100, Protease inhibitor cocktail], and cell debris 
was removed by centrifugation at 20 000 x g for 15 min. The lysates were first 
incubated with Protein G Magnetic Beads (Pierce/Thermo Scientific) for 30 min at 
4°C to remove unspecifically bound material, and then with Strep-Tactin
®
 XT 
Magnetic Beads (IBA Lifesciences) o/n. After washing the beads twice with lysis 
buffer and 10 mM HEPES (pH 7.6), 150 mM NaCl, the samples were solubilized in 
0.2% RapiGest SF (Waters Inc., Milford, MA). The protein concentration was 
determined with the BCA protein assay (Thermo Fisher Scientific, Waltham, MA, 
USA) and the samples were adjusted to a final protein amount of 10 µg in 50 µl in 
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AMBIC (Thermo Fisher Scientific). On-beads digestion was conducted with the In-
solution tryptic digestion and guanidination kit (Thermo Fisher Scientific) without 
guanidination. After digesting the samples overnight, formic acid was added ad 0.1%, 
followed by a 45-min incubation at 37 °C and 15-min centrifugation at 13,000 rpm. 
Tryptic peptides were further cleaned using Pierce C18 spin columns (Thermo Fisher 
Scientific). Eluted peptides were dried in a speed vac, and resuspended in 0.1% 
formic acid. Samples were loaded into an Easy-nLC 1200 (Thermo Fisher Scientific) 
in 250 µl autosampler microvials. Chromatographic separation of 100 ng of peptides 
was carried out in commercially packed Acclaim PepMap C18 columns (2 mm, 100 
Å, 75 mm, 15 cm) (Thermo Fisher Scientific). Peptides were loaded in buffer A (5% 
acetonitrile and 0.1% formic acid) and eluted with a 1-hour linear gradient from 5% to 
30% buffer B (80% acetonitrile and 0.1% formic acid). Each sample was run three 
times, with 15-min wash runs between every injection. Mass spectra were acquired 
using a Top N data-dependent method with an automatic switch between full MS and 
MS/MS (MS2) scans with an Orbitrap Fusion instrument (Thermo Fisher Scientific). 
The acquisition parameters for the full MS scan were 120,000 resolution, 350 to 1800 
m/z mass range, and a 4e5 ions AGC target, followed by a 30,000 resolution and 5e4 
ions AGC target, with a 2 m/z isolation window and a 30 s dynamic exclusion for 
MS2 spectra acquisition. Protein groups identification and quantification were carried 
out with MaxQuant v. 1.6.1.0 (29) using the UniProtKB FASTA file for human 
containing 86725 entries, to which 245 common contaminants and all reverse 
sequences were added. Data was extracted and filtered for further analysis using the 
Perseus data analysis software v. 1.6.5.0 (30). Histone and ribosomal peptide IDs 
were removed as putative contaminants, and only peptide IDs with >5-fold 
enrichment in the ORP2-2xStrep sample compared to control sample were included in 
the final data set. 
 
Cell morphology assessment  
The morphology of the shORP2 HUVECs as compared to the controls was assessed 
visually under a bright-field microscope and images were acquired with an Evos XL 
Cell Imaging System (AMG; Thermo Fisher Scientific). Changes in actin 
cytoskeleton morphology were visualized by Oregon green phalloidin dye and in 
focal adhesions by anti-phospho-paxillin(Tyr118) antibody with a Zeiss Axio 
 11 
Observer Z1 fluorescent microscope. The cell spreading/perimeter analysis was 
conducted with ImageJ particle analysis function for >200 cells (n=3). 
 
EC migration assays 
Endothelial cell migration was assessed both under planar unstimulated conditions 
and as growth factor-stimulated directional trans-filter movement in real-time. 
The planar migration was monitored using IncuCyte ZOOM Scratch 
Wound assay (Essen BioScience, Hertfordshire, UK). 3x10
4
 HUVECs were seeded in 
a 96-well Image Lock plate along with control or ORP2 shRNA lentivirus in complete 
ECGM2 media. Cells were incubated for 48 h at 37ᵒC in a humidified atmosphere 
with 5% CO2, followed by antibiotic selection using 2.5 µg/ml puromycin for 24 h. 
For wound healing assay, a uniform scratch wound was made in each well using 
IncuCyte Wound maker. Wells were then rinsed with PBS to remove floating cells 
and fresh ECGM2 complete media was added. Cell migration was imaged using 
IncuCyte Zoom microscope for 24 h with 2-h intervals using a 4x objective. Relative 
wound density was used to quantify wound closure using IncuCyte Cell migration 
software. 
The trans-filter migration of control or ORP2 shRNA transduced 
HUVECs was measured with xCELLigence
TM
 Real-Time Cell Analysis system 
equipped with a DP instrument (ACEA Biosciences, San Diego, CA). After 48-h 
lentiviral transduction and puromycin selection (as described earlier), the cells were 
starved for 2 h (ECGM2 without supplements) and then seeded at a density of 3x10
4 
cells/well into upper chamber of xCELLigence CIM-plate
TM
 16 (ACEA Biosciences) 
containing starvation media. The wells of the lower chamber were loaded with 
ECGM2 media with double supplements and 50 ng/ml VEGF-A (R&D Systems). The 
stimulated directional trans-filter cell migration from the upper to the lower chamber 
was detected by electrical impedance for 24 h at 10-minute intervals. The 
measurements were performed at 37°C, in a humidified 5% CO2 atmosphere and 
recorded with Real-Time Cell Analysis (RTCA) Software 1.2 (ACEA Biosciences). 
 
EC viability and proliferation measurements  
To determine the effects of ORP2 KD on cell survival, we performed a viability assay 
based on the enzymatic reduction of the tetrazolium salt MTT (Thermo Scientific) by 
metabolically active cells. HUVECs were seeded in 96-well microtiter plates in 
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ECGM2 medium and allowed to attach for 24 h. After confluency was reached, the 
cells were starved for 2 h and treated with 50 ng/ml of VEGF (R&D Systems) for 12 
h. The cell viability was determined by incubating the cells for 4 h at 37°C with 5 
mg/ml MTT, following removal of medium and cell solubilization into 100 µl of 
DMSO. The colorimetric change of MTT was measured at 570 nm with EnSpire 
fluorometer/multimode plate reader (Perkin Elmer). The results are shown as mean ± 
SD of 4 independent experiments, each with 5 replicate wells. The real-time 
proliferation efficiency of ORP2 KD HUVECs was determined by xCELLigence® 
instrument as described in (10). 
 
 
Cell fractionation for lipid raft isolation 
For detergent-free lipid raft isolation, shORP2 and shCTRL lenti-transduced 
HUVECs (approximately 2x10
6
 cells/sample) were collected by scraping into PBS, 
pelleted by centrifugation at 200 x g for 5 min and resuspended into 0.5 M sodium 
carbonate buffer (pH 11.0) containing protease inhibitor cocktail (Roche, Basel, 
Switzerland). The cells were homogenized by forcing them 150 x through a 23-gauge 
needle. Subsequently, the samples were adjusted to 45% sucrose by addition of 90% 
sucrose and transferred into ultracentrifuge tubes. A 5% to 35% discontinuous sucrose 
gradient was generated on top of the samples (6), and ultracentrifugation was carried 
out at 190,000 x g for 22 h in a TLS-55 swinging bucket rotor (Beckman, Brea, CA). 
After the centrifugation, nine fractions were collected from the top. The light 
membrane fraction, i.e. the lipid raft fraction (fraction 4), as well as fractions 5 & 6 
were selected for further analysis. The distribution of VEGFR2, Flotillin-1 and -
tubulin between the membrane and the soluble fractions were analyzed by western 
blot with the respective antibodies. Cholesterol content of the gradient fractions was 
measured by using the Amplex Red assay (Thermo Fisher Scientific) and normalized 
by the protein content of the fractions (BCA assay, Pierce/Thermo Fisher Scientific).  
 
VEGF receptor biotinylation assay 
To isolate the surface pool of VEGFR2 in HUVECs, the cell surface proteins of 
shORP2 or shCTRL lenti-transduced cells were biotinylated with the membrane 
impermeable Sulfo-NHS-SS-biotin reagent (Thermo Scientific) according to the 
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manufacturer’s protocol. After biotinylation the cells were washed three times with 
quenching buffer (50 mM Tris, pH 8.0) and lysed into 10 mM HEPES (pH 7.6), 150 
mM NaCl, 0.5 mM MgCl2, 10% glycerol, 0.5% Triton X-100, 0.5% sodium 
deoxycholate containing protease inhibitor cocktail. The cell debris was removed by 
centrifugation at 14 000 x g for 10 min at 4°C, after which a sample was taken from 
the supernatant representing the total pool of VEGFR2. The rest of the lysate was 
mixed with NeutrAvidin agarose beads (Thermo Scientific) and incubated in rotation 
for 4 h. The beads were collected and washed twice with lysis buffer, and the bead-
bound cell surface receptors extracted for western blot by boiling with SDS-PAGE 
sample buffer. The remaining lysate represented the intracellular VEGFR2 pool. 
 
Plasma membrane cholesterol depletion & loading 
The PM cholesterol of HUVECs was depleted by 30-60-min incubations with 4.6 mM 
methyl-β-cyclodextrin (MβCD) at 37°C. PM cholesterol rescue of the in vitro 
angiogenic tube formation assay was performed by 3-hour incubation with 4 mM 
MβCD-cholesterol at 37°C. Both the MβCD and the MβCD-cholesterol complex were 
purchased from Sigma-Aldrich.  
 
Generation of ORP2 knock-out (KO) mice by CRISPR/Cas9 
Osbpl2(ORP2) KO mice were generated by Shanghai Biomodel Organism Science 
and Technology Development Co., Ltd. by CRISPR/Cas9. Exon 3 of Osbpl2 was 
removed by targeting its flanking intronic regions with four gRNAs (Supplementary 
Fig. S1A-D). The gRNAs and Cas9 mRNA were produced by in vitro transcription 
and microinjected into fertilized C57BL/6J eggs. From the F0 mice, the Osbpl2 gene 
region was PCR amplified and sequenced via a T-vector. Founders with deletions 
removing exon 3 were selected for further breeding. In these animals, Osbpl2 protein 
translation is halted by a premature termination codon, resulting in a truncated protein 
of 31 amino acid residues: MNGEEEFFDAVTGQPFLLPCSPEATSVCGVS. In this 
study we only investigated the retinal vasculature of the KO animals, relevant for the 
present topic. The animal experiments were approved by the Ethics Committee for 
Animal Experiments of Jinan University and performed in compliance with the China 
government guidelines. Mice were housed in sterilized filter-top cages and given 
unlimited access to food and water with 12/12-h dark/light cycle.  
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Retinal vasculature analysis of ORP2 KO mice   
Eyes from humanely terminated postnatal day 7 (P7) mouse pups were enucleated 
into cold PBS and fixed in 4% paraformaldehyde (PFA) at 4°C for 2 h. Then the eyes 
were transferred into cold PBS on ice for 5 - 10 min. Retinas were dissected, created 
into a 'petal' shape, and fixed in MeOH at −20°C. After brief washes in cold PBS, 
retinas were incubated in 100 μl of Perm/Block solution (PBS, 0.3% Triton, 0.2% 
BSA) + 5% fetal calf serum and shaken gently for 1 h. After removing the 
Perm/Block solution the retinas were incubated with gentle shaking overnight at 4 °C 
with 100 μl FITC-conjugated Isolectin B4 (Sigma-Aldrich, 40 μg/mL in Perm/Block). 
After four washes in PBS, 0.3% Triton X-100, retinas were transferred onto 
microscope slides and imaged with a confocal microscope (Olympus FV3000). All 
images were photo-merged with Toupview and analyzed with Image Pro Plus 6.0. 
 
Gene expression analysis in mouse endothelia 
Total RNA was isolated from P7 mouse pups retina with TRIzol reagent 
(Invitrogen/Thermo Scientific) according to the manufacturer’s instructions. RNA 
samples were reverse transcribed by the PrimeScript™ RT reagent Kit with gDNA 
Eraser (Takara Bio, Kusatsu, JP). qRT-PCR was performed with TB Green™ Premix 
Ex Taq™ (Takara Bio) using a instrument CFX 96 (Bio-Rad) and analyzed by CFX 
ManagerTM software using -CT method, with actin as an endogenous reference. 
Relative expression is represented as the ratio of target gene to reference from 




ORP2 controls the distribution of cholesterol in HUVECs 
We and others recently proposed that ORP2 is involved in the intracellular delivery of 
cholesterol to the PM in HeLa cells (16, 17). As efficient cholesterol transport is 
particularly important for the maintenance of healthy endothelia, we investigated the 
effects of ORP2 on cholesterol distribution in primary endothelial cells, HUVECs. 
The cells were transfected with the cholesterol-binding domain 4 of C. perfringens 
theta-toxin fused with mCherry (mCherry-D4H) and with either ORP2 specific or 
control siRNA (Supplementary Fig. S2A). The cells were imaged, and the distribution 
of the D4H probe between LEs and the PM was quantified by visual inspection of the 
mCherry-D4H-expressing cells (>300 cells were analyzed).  
As reported for HeLa cells, ORP2 KD caused perturbations in the 
distribution of D4H-accessible cholesterol between endosomes and PM also in 
HUVECs. In the control cells, the mCherry-D4H cholesterol probe typically 
distributed to both the LEs and the PM, while in the majority (~60%) of D4H-
expressing ORP2 KD cells the D4H-bound pool of cholesterol accumulated into 
LAMP1-positive late endosomal compartments (Fig. 1A, B). Moreover, the cells 
depleted of ORP2 showed a significantly reduced distribution of mCherry-D4H to the 
PM. 
Consistently, overexpression of wild type (wt) ORP2-pEGFP-C1 
(Supplementary Fig. S2A) in HUVECs shifted the D4H-bound cholesterol towards 
the PM, seen as significantly increased PM localization of the D4H probe compared 
to cells transfected with the pEGFP-C1 vector control (Fig.1C, D). Of note, in 
HUVECs overexpressing either sterol or PIP-binding deficient mutants of ORP2, 
ORP2(∆ELSK) or ORP2(mHHK) (Supplementary Fig. S2A), respectively, the D4H 
probe accumulated to late endosomes similar to the ORP2 KD cells (Fig. 1C, D), 
suggesting a crucial role for both sterol and PIP-binding in the ORP2-mediated 
cholesterol redistribution.  
 Cholesterol content in plasma membranes isolated from the control and 
ORP2 KD cells was measured with Amplex Red assay. These experiments did not 
reveal a significant reduction of the PM total cholesterol content in the ORP2 KD 
HUVECs, albeit the mean measured for the KD cells showed a reducing trend (Fig. 
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2A). We next assayed the interaction of the cholesterol probe His6-ALOD4 with the 
mobile extracellular leaflet cholesterol in the KD and control cells. Similar to the PM 
total cholesterol measurement, no difference was observed in the association of the 
probe with cell surfaces on ORP2 KD and control cells, while extraction of PM 
cholesterol with MCD strongly reduced the cellular association of the probe (Fig. 
2B). These observations suggest that the impact of ORP2 depletion may rather affect 
the PM cholesterol organization than its bulk amount in HUVECs.  
 
ORP2 controls the PM PI(4,5)P2 content 
 As ORP2 was reported to act as an exchange-type ‘countercurrent 
transporter’ of cholesterol and PI(4,5)P2 (17), we quantified the PI(4,5)P2 
concentration in the inner leaflet of the PM of HUVECs in the absence or presence of 
ORP2 KD using the epsin 1 ENTH domain as a PI(4,5)P2 sensor. As observed with 
other mammalian cell lines (20-22), HUVECs showed a spatially heterogeneous 
distribution of PI(4,5)P2 in the inner leaflet of the PM (Fig. 2C). The spatially 
averaged concentration was 0.30 ± 0.10 mol% and remained essentially constant for 
at least 10 min. This value is significantly lower than that observed with several cell 
lines, such as NIH 3T3 (20-22), which may suggest a lower basal level of PI(4,5)P2-
dependent activities at the PM of the resting primary HUVECs than in transformed 
cell lines. The ORP2 KD caused ca. 2.5-fold increase (i.e., to 0.75 ± 0.09 mol%) in 
the spatially averaged PM concentration of PI(4,5)P2, consistent with the view that 
ORP2 indeed transfers PI(4,5)P2 to the internal membrane organelles in exchange for 
cholesterol. 
The PM PI(4,5)P2 content of the ORP2 KD and control HUVECs was 
also measured biochemically. We isolated the PM of the cells, then extracted the PM 
lipids and subsequently measured the PI(4,5)P2 content by utilizing a competitive 
PI(4,5)P2 ELISA assay (Echelon Biosciences). The results showed significantly 
increased PI(4,5)P2 concentrations for ORP2 KD PM samples as compared to the 
controls (Fig. 2D), validating the results obtained from the PI(4,5)P2 probe assay. 
 
ORP2 overexpression enhances protrusion formation in HUVECs 
We recently showed that ORP2 localized to cortactin-positive lamellipodia and 
enhanced polarized cell protrusions when overexpressed in HuH7 hepatoma cells 
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(10). Here, we examined whether ORP2 overexpression has similar effects on primary 
endothelial cells. In accordance with our previous report, we found that ORP2 
enhanced protrusion formation also in HUVECs (Fig. 3A, B). A majority (86%) of 
the cells expressing ORP2(wt) presented with prominent PM protrusions, whereas 
only less than 30% of the GFP-expressing control cells showed protrusions under the 
basal culture conditions (Fig. 3B). Interestingly, the ORP2-mediated enhancement in 
protrusion formation seemed to depend on ORP2’s ability to bind both sterols and 
PIPs, since the ORP2(ΔELSK) and ORP2(mHHK) mutants were unable to provoke 
PM protrusions (Fig. 3B).  
 
ORP2 KD inhibits angiogenic tube formation in vitro  
Efficient cholesterol trafficking and protrusion formation are crucial for EC sprouting 
and angiogenesis. Since ORP2 had drastic effects on both of these cellular processes, 
we assessed the possible effect of ORP2 on angiogenic tube formation in vitro. ORP2 
was depleted from HUVECs by lentiviral transduction and the tube forming ability of 
the transduced cells was studied by seeding them on a matrix supplemented with 
endothelial growth factors. The cells were imaged at five hours after seeding, and the 
tube formation parameters were analyzed from images. ORP2 KD drastically 
inhibited the formation of the EC tubular network (Fig. 3C, D). For example, the 
number of tubule nodes and junctions were both reduced by approximately 70%, the 
number of meshes and tube segments by over 80%, the number of branching points 
by 46%, and total branch length by 83% as compared to control HUVECs. Of note, 
the angiogenesis inhibitory effect of ORP2 KD was partly rescued when the cells 
were loaded with external cholesterol by 3-hour incubation with MCD-cholesterol 
complex (Fig. 3C, D). In the control cells, however, similar cholesterol loading 
inhibited the angiogenic tube formation, underscoring the importance of a physiologic 
cholesterol content or organization for the process (Fig. 3C, D). 
 
ORP2 KD alters the gene expression profiles of multiple angiogenic pathways 
To study whether the angiogenic defects of ORP2 KD HUVECs are associated with 
changes of the transcriptome, we performed a next-generation RNA sequencing 
(RNAseq) of the lentivirally transduced ORP2 KD HUVECs. The differential 
RNAseq analysis revealed significantly (Log2 fold change > 1) altered mRNA 
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profiles for more than 1000 genes as compared to the control shRNA-transduced 
HUVECs. Interestingly, by utilizing the ConsensusPathDB gene set over-
representation tool (28) to assess the affected signaling pathways in the ORP2-
depleted HUVECs, we found significantly (adjusted p<0.05) altered gene expression 
in several pathways associated with angiogenesis (Table 1). Strikingly, the VEGF-
VEGFR2 pathway was the single most significantly affected signaling pathway in the 
ORP2 KD HUVECs, with as many as 76.7% of either up- or downregulated 
overlapping gene IDs (Table 1, Supplementary Fig. S3A). In addition, pathways 
related to e.g. Rho GTPase, epidermal growth factor receptor (EGFR), focal adhesion 
kinase (FAK), Notch, mammalian target of rapamycin (mTOR), hypoxia inducible 
factor-1- (HIF-1-), phosphoinositide 3 kinase/protein kinase B (PI3K/Akt), and 
mitogen activated protein kinase (MAPK) signaling were among the angiogenic 
signaling pathways affected in the ORP2-depleted cells (Table 1). Moreover, a 
number of angiogenesis-initiating cellular functions downstream of the prementioned 
signaling pathways such as ‘cell proliferation’, ‘cytoskeleton organization’, ‘cell 
motility’ and ‘cell adhesion’, were predicted to be affected in the ORP2 KD HUVECs 
by gene ontology (GO) analysis (Supplementary Table S2). Consistently, also 
angiogenesis itself, alongside with e.g. ‘vasculature development’, ‘tube 
morphogenesis’ and ‘blood vessel remodeling’ were predicted as significantly 
affected biological processes in the ORP2 KD HUVECs (Table 2).  
 
ORP2 KD alters the expression of several genes regulating cholesterol 
homeostasis and plasma membrane lipid organization 
To assess the mRNA alterations in ORP2 KD HUVECs putatively responsible for the 
defects in cholesterol transport, the RNAseq data was searched for significantly 
affected signaling pathways and cell functions associated with cholesterol 
homeostasis and transfer. The ConsesusPathDB analysis uncovered the major 
cholesterol homeostasis coordinating pathway, ‘sterol regulatory element-binding 
protein (SREBP) signaling’, as one of the most significantly affected signaling 
pathways in ORP2 KD cells, with 80.9% of overlapping genes (see full list of 
significantly affected SREBP target genes in Supplementary Table S3). In addition, 
processes such as ‘sterol biosynthesis and metabolism’, ‘LDL particle clearance’ and 
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‘cholesterol storage’ were among the significantly affected cellular functions 
predicted by the ConsensusPathDB GO analysis (Table 3).  
As ORP2 is suggested to transport cholesterol towards the PM, we wondered 
whether the expression of genes regulating PM cholesterol-rich raft domains was 
altered in ORP2 KD HUVECs. Since lipid raft-associated proteins as a category are 
not included in the pathway databases used (Wikipathway, KEGG, Reactome and 
PID), we ran a separate comparison of the ORP2 KD RNAseq data against the 
RaftProt database (31), available at http://raftprot.org. The analysis revealed that 
69.4% of the gene IDs found in the RaftProt database were significantly affected in 
ORP2 KD HUVECs. Moreover, ‘PM organization’, ‘membrane raft organization’, 
and ‘membrane raft assembly’ were among the significantly enriched GO terms in the 
ConsensusPathDB analysis (Table 3).   
 
ORP2 regulates the activity of VEGFR2 and several of its downstream targets 
Encouraged by the RNAseq analysis suggesting ‘VEGF-VEGFR2 signaling’ as the 
most significantly affected pathway in OPR2 KD HUVECs, the activity of this 
pathway and its major regulatory nodes was studied by western blot analysis. 
HUVECs were stimulated with VEGF-A165 for 0, 3, or 12 min and the 
phosphorylation of VEGFR2(Tyr1175), Akt(Ser473), p70S6 kinase(Thr398), a 
marker for mTOR activity,  ERK1/2(Thr202/Tyr204), eNOS(Ser117) and 
FAK(Tyr397) were detected by the respective phospho-specific antibodies. These 
angiogenic effectors are responsible for mediating extracellular angiogenic signal 
transduction (VEGFR2), cell survival and energy metabolism (Akt, mTOR), cell 
proliferation (ERK1/2), nitric oxide production and cell permeability (eNOS), and cell 
adhesion and migration (FAK). The analysis uncovered that the ORP2 KD resulted in 
a decreased activating phosphorylation of the 230-kDa VEGFR2 at both the 3-min 
and the 12-min time points of the VEGF stimulus (Fig. 4A). Quantification of the 12-
min time point showed a drastic 59%  11% reduction in the phospho-VEGFR2 
signal in the ORP2 KD cells as compared to control (the phospho-antibody signal was 
normalized by the total protein signals of the respective samples, Supplementary Fig. 
S2B). Moreover, ORP2 KD resulted in a significant inhibition of the activating 
phosphorylation of VEGFR2 downstream targets Akt (−46  5%), eNOS3 (−50  
8%), and p70S6K (−31  7%) upon 12-min VEGF stimulus as compared to the 
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controls (Fig. 4B, Supplementary Fig. S2C). There was no significant difference in 
the activating phosphorylation of FAK, and changes in the activity of ERK1/2 were 
inconsistent (data not shown). Of note, PM cholesterol depletion mediated by MCD 
decreased the activity of VEGFR2, Akt, eNOS, and p70S6K similarly to ORP2 KD 
upon 12-min VEGF stimulus (Fig. 4C, Supplementary Fig. S2C). 
ORP2 KD decreases the expression of Caveolin-1 and VE-cadherin 
The mRNA sequencing (RNAseq) data of ORP2 KD cells revealed downregulation of 
several genes encoding raft-associated proteins. Among these were proteins such as 
Caveolin-1, Flotillin-1, Annexin A2 and vascular endothelial cadherin (VE-cadherin). 
To assess the effects of ORP2 KD on these raft components at the protein level, we 
compared their expression levels between ORP2 KD and control cells by western 
blot. The immunodetection revealed that the expression of Caveolin-1, a major 
structural component of caveolae, and VE-cadherin, a mediator of cell-cell contacts, 
were significantly decreased in ORP2 KD HUVECs (−58  3% and −65  18%, 
respectively) as compared to control levels (Fig. 4D), suggesting alterations in PM 
caveolae or lipid rafts. The expression levels of Flotillin-1 and Annexin A2, however, 
remained unchanged between ORP2 KD and control cells (Fig. 4E).  
 
ORP2 KD impairs several angiogenic cell functions  
GO analysis of the ORP2 KD RNAseq data predicted several angiogenic cell 
functions downstream of VEGF signaling, such as ‘cell cycle’, ‘cell migration’ and 
‘actin cytoskeleton organization’ to be significantly modified in ORP2-depleted 
HUVECs (Supplementary Table S2). We therefore tested whether these cell functions 
were altered in the ORP2 KD HUVECs. 
To determine the effects of ORP2 KD on cell proliferation and survival, we 
employed (i) a microelectrode-based xCELLigence® real-time cell analysis system 
and (ii) a viability assay based on the enzymatic reduction of the tetrazolium salt 
MTT by metabolically active cells. ORP2 KD reduced the xCELLigence® 
proliferation signal by 44.7%  6.6% (at a 12-h time point) as compared to HUVECs 
transduced with non-target control virus (Fig. 5A). Consistently, in the MTT viability 
assay the ability of VEGF-A165 (50 ng/ml) to stimulate EC survival after a 12-h 
incubation was significantly decreased (−40.7  8.0%) in the HUVECs transduced 
with shORP2 lentivirus compared to the controls (Fig.5B).   
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One of the most affected cellular functions in the RNAseq of ORP2 depleted 
HUVECs was cell mobility and migration. We therefore studied the migration 
capacity of ORP2 KD HUVECs by (i) planar wound healing assays and (ii) a real-
time xCELLigence® trans-filter migration application. These independent methods 
revealed impaired ability for ORP2-depleted ECs to migrate under basal and growth-
factor-stimulated conditions, respectively (Fig. 5C-E). The wound closure of ORP2 
KD HUVECs showed 40.9%  25.2% reduction under basal growth conditions as 
compared to the control cells (Fig. 5C,D). Consistently, the directed trans-filter 
migration of ORP2 KD cells was inhibited by 44.4%  19.5% as compared to control 
HUVECs in the xCELLigence® analysis (Fig. 5E).  
The effects of ORP2 KD on overall cell morphology and shape were assessed 
by observing the cells under a bright-field microscope. ORP2 KD HUVECs typically 
had an elongated and spread-out cell shape distinct from the controls (Fig. 5F). 
Analysis of cell dimensions of the ORP2 KD and control cells showed a significant 
increase (+42.2%  7.7%) in surface area covered by an individual ORP2 KD cell as 
compared to a control cell, suggesting increased spreading of the KD cells on the 
substratum. To study the effects of ORP2 KD on cytoskeletal morphology in 
HUVECs, the cells were stained with Oregon green phalloidin to visualize F-actin 
stress fibers. Interestingly, ORP2 KD promoted the formation of an abnormal actin 
stress fiber morphology: The fibers/fiber bundles were thicker and more co-aligned 
than in the control cells (Fig. 5G). Immunostaining of active focal adhesions of ORP2 
KD and control HUVECs by anti-phospho-paxillin revealed an altered, aligned 
distribution also for focal adhesions in the ORP2 KD cells (Fig. 5G). Together, these 
observations imply that in endothelial cells ORP2 KD results in an altered 
cytoskeletal morphology and cell anchoring to the substratum, as predicted by the GO 
analysis of RNAseq results.  
 
ORP2 protein interactome overlaps with the VEGFR signaling pathway and the 
lipid raft proteome 
To further characterize the molecular mechanisms by which ORP2 affects EC 
homeostasis, we carried out a pull down-based mass spectrometric analysis of ORP2 
binding partners in HUVECs. The analysis revealed 464 proteins that were enriched 
>5 fold in the ORP2-2xStrep sample as compared to the negative control (a full list of 
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ORP2-2xStrep interactome in HUVECs  in avaiulanble upion request from the 
authors). Intriguingly, the ConsensusPathDB analysis of the ORP2 interactome 
revealed VEGF-VEGFR2 signaling as one of the most significant (p=1.65
-08
) 
angiogenic pathways with several overlapping gene IDs, consistent with the findings 
of the ORP2 KD RNAseq data. Other angiogenic signaling pathways shared between 
the ORP2 KD RNAseq data and the ORP2 interactome were e.g. Rho GTPase, TGF-
β, EGF-EGFR, PDGFR-β, FAK, PI3K/Akt, HIF-1-α and MAPK signaling (Table 1). 
In addition, many of the angiogenic cell functions downstream of VEGFR2 and 
predicted to be affected in the RNAseq data were included also in the GO hits of the 
interactome data. For example, ‘cell cycle’, ‘cytoskeleton organization’, ‘cell 
motility’ and ‘cell adhesion’ overlapped in both of these independent data sets, 
suggesting that a major part of these observations reflect specific ORP2 functions. Of 
note, also ‘vasculature development’, ‘tube morphogenesis and development’, 
‘sprouting angiogenesis’ and ‘cellular response to hypoxia’ were among the GO terms 
shared between the ORP2 KD RNAseq and the interactome data. Moreover, 328/464 
(70.7%) of the identified interaction partners of ORP2 overlapped with the lipid raft-
associated proteins listed in the RaftProt database. Intriguingly, most of the putative 
interaction partners of ORP2 that were associated with the VEGF-VEGFR2 pathway 
were reported to be associated also with lipid rafts by the RaftProt database 
(Supplementary Fig. S3B), supporting a connection between the ORP2 regulation of 
angiogenic tube formation and cholesterol-enriched PM domains. 
 
ORP2 KD reduces compartmentalization of VEGFR2 to the buoyant lipid raft 
membrane fractions 
VEGFR2 is associated with PM lipid rafts, a location shown to be of importance in 
regulating the activity of the receptor (3, 6). To study the mechanism by which ORP2 
contributes to VEGFR2 activity, we assessed by detergent-free cell fractionation 
whether ORP2 KD affected the association of VEGFR2 with HUVEC raft domains. 
The membrane fractionation experiments showed a marked reduction in the relative 
abundance of VEGFR2 in the buoyant lipid raft-fraction (fraction 4) in the ORP2 KD 
HUVECs compared to the control cells (Fig. 6A, B), suggesting that the depletion of 
ORP2 causes a redistribution of VEGFR2 away from the buoyant raft membrane 
domains. As the lipid raft-association of VEGFR2 has been previously shown to be 
dependent on the PM cholesterol content (3, 6), we next analyzed the amount of 
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cholesterol in the ORP2 KD membrane fractions. This analysis revealed a significant 
reduction in the relative concentration of cholesterol in the lipid raft fraction (fraction 
4) of ORP2 KD cells as compared to the control, while the cholesterol content of the 
heavier membrane fractions 5 & 6 significantly increased in the ORP2 KD cells as 
compared to the control (Fig. 6C). 
 
ORP2 KD increases VEGF receptor cleavage at the PM  
To further study the effects of ORP2 KD on the PM-associated VEGFR2 we 
performed surface receptor biotinylation assays to isolate the PM pool of the receptor. 
Interestingly, ORP2 KD significantly increased the portion of PM-associated C-
terminal 130 kDa cleaved residue of the biotinylated VEGFR2 as compared to control 
cells (Fig. 6D, E). Notably, the 130 kDa residue was nearly invisible in the 
intracellular pool of the VEGFR2, suggesting that the cleavage occurred specifically 
at the cell surface (Fig. 6D). VEGFR2 has been reported to be cleaved at the PM by 
TNF-converting enzyme (TACE or ADAM17), a matrix metalloproteinase (MMP) 
sequestered in lipid rafts (32, 33). To examine whether the increased VEGFR2 
cleavage at the PM of ORP2 KD cells is catalyzed by MMPs, we treated the cells with 
5 µM Marimastat, an MMP inhibitor, and repeated the biotinylation assay. 
Interestingly, the Marimastat treatment completely abolished the 130 kDa cleaved 
form of VEGFR2 in the ORP2 KD cells (and in the controls) (Fig. 6F), demonstrating 
that the enhanced VEGFR2 cleavage upon ORP2 depletion is due to increased 
susceptibility of the receptor to MMPs.  
To confirm that the VEGFR2 cleavage is specific for changes in ORP2 
expression, we lentivirally overexpressed the wild type ORP2 in HUVECs and 
checked whether it had an effect on generation of the 130 kDa VEGFR2 residue. 
Interestingly, the overexpression of ORP2 significantly alleviated the VEGR2 
cleavage, confirming that the cleavage of VEGFR2 at the PM was indeed modulated 
by the availability of ORP2 (Fig. 6G). 
 The shedding by ADAM17 of its substrates has been shown to depend 
on the PM raft cholesterol (33, 34). Therefore, we next assessed whether the increase 
in MMP-mediated VEGFR2 cleavage upon ORP2 KD could be due to a modification 
of PM cholesterol organization. To this end, we depleted cholesterol from the PM of 
untransduced HUVECs by a time series of MCD incubations and repeated the 
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receptor biotinylation assay. Intriguingly, a time-dependent increase in the 130 kDa 
residue of VEGFR2 was observed at the PM of the cholesterol depleted cells (Fig. 
6H), suggesting cholesterol-dependency of the receptor shedding. Moreover, also this 
MCD-mediated increase in VEGFR2 shedding at the PM could be rescued by 
Marimastat treatment. 
 As VEGFR2 shedding by MMPs releases the N-terminal VEGF-binding 
domain of the receptor, we wondered whether the receptor cleavage upon ORP2 KD 
could be the cause for the reduced phosphorylation of the 230 kDa receptor in the PM 
of the KD cells. To test this hypothesis, we again treated the ORP2 KD cells with 
Marimastat o/n, stimulated them with VEGF-A for 12 min and detected the VEGFR2 
phosphorylation by western blot. The reduction in the phosphorylation of VEGFR2 in 
the ORP2 KD cells was completely rescued by the Marimastat treatment (Fig 6I). 
These data, together with the above cell fractionation observations suggest that the 
primary mechanism by which ORP2 modulates VEGFR cleavage and 
phosphorylation at the PM is via alterations in the PM cholesterol organization, 
resulting in a redistribution of VEGFR2 to a location where it is sensitized to MMP 
activity. The reduced phosphorylation of the 230-kDa VEGFR2 is, according to our 
data, secondary to proteolytic cleavage of a receptor pool at the PM. 
 
ORP2 KO interferes with retinal vasculature development in vivo in mice  
To investigate whether the lack of ORP2 interferes with angiogenesis in vivo, we 
generated global Osbpl2 KO mice by deleting the Osbpl2 exon 3 by CRISPR/Cas9-
mediated gene targeting. This resulted in viable and superficially healthy animals with 
an allele encoding a truncated Osbpl2 protein spanning only the first 31 aa residues of 
the protein. Western blot analysis of the brain of the animals verified a lack of 
immunoreactive Osbpl2 protein in the Osbpl2
-/-
 animals and an approximately 50% 
reduction in the heterozygotes (Supplementary Fig. S1). We then imaged the 
microvasculature in the retina by isolectin B4 staining of post-natal day 7 Osbpl2 
(ORP2) knock-out and littermate control mice. This revealed a subtle but significant 
alteration of morphology characterized by reduced vessel length and increased density 
of tip cells and perpendicular sprouts in both the front and the central areas of the 
retinal vasculature (Fig. 7A-D). The increase of tip cells and sprouts suggested a 
possible disturbance of Notch signaling. Consistent with this notion the qPCR 
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analysis of retina revealed significantly reduced mRNA expression of the Notch 
pathway components Cyclin D1 (CCND1), Delta-like 1 (DLL1), Jagged 1 (JAG1) 
and signal transducer and activator of transcription 1 (STAT1) (Fig. 7E). Of note, also 
in the RNAseq of ORP2 KD HUVECs the Notch pathway was significantly affected 
(Table 1), and the above four genes dampened in the Osbpl2
-/-
 mouse retina were 
consistently downregulated in the HUVEC model (Fig. 7E). Importantly, analysis of 
retinal mRNA expression levels also revealed a significant down-regulation of Cdh5 
(VE-cadherin) as well as of top cholesterol biosynthetic genes suppressed in the 
HUVEC model, Fdft1 and Srebp-2 (p=0.06), as well as mTOR, a hub involved in 
VEGF, Notch and SREBP signaling (35-37). These observations lend support to the 
notion that cholesterol homeostasis, VE-cadherin dependent EC adhesion and 
intercellular Notch signaling are affected in both the HUVEC model and in ORP2 KO 





In the present study we report a crucial functional role of the intracellular cholesterol 
and PI(4,5)P2 transporter ORP2 in endothelial cells, a cell type playing decisive roles 
in common diseases such as cardiovascular diseases, type 2 diabetes and cancers. We 
show in primary human endothelial cells that ORP2 knock-down, or the 
overexpression of its mutants defective in sterol or phosphoinositide binding, alter the 
subcellular distribution of cholesterol as detected with the D4H probe, and 
demonstrate that ORP2 manipulations affect the formation of HUVEC surface 
protrusions in a ligand-dependent manner. As a key finding we show that ORP2 KD 
in HUVECs inhibits angiogenesis in vitro in a tube-forming assay and its loss in vivo 
in a knock-out mouse model results in a subtle alteration of retinal angiogenesis. 
Consistent with the above observations, RNA sequencing revealed that ORP2 knock-
down in HUVECs induced significant changes in the gene expression of multiple 
angiogenic pathways and cell functions. Our data also demonstrates that ORP2 KD 
attenuates the migration and proliferation capacity of HUVECs and impairs their 
viability. As key mechanistic observations we show impaired VEGF signaling in 
HUVECs subjected to ORP2 KD, featured by defective activating phosphorylation of 
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VEGFR2, Akt, eNOS, and p70S6K. We further demonstrate that ORP2 depletion 
reduces cholesterol in the buoyant lipid raft domains, shifts VEGFR2 away from these 
domains, induces enhanced proteolytic cleavage of VEGFR2 by MMPs and dampens 
expression of the raft-associated proteins Caveolin 1 and VE-cadherin, consistent with 
the view that ORP2 KD disturbs cholesterol-dependent functional domains at the EC 
plasma membrane.  
VEGFR2 signaling and angiogenesis are thought to require distribution of the 
receptor into lipid rafts. Liver X receptor activation inhibits angiogenesis through 
enhancement of cholesterol efflux resulting in the removal of VEGFR2 from raft 
domains (3). Consistently, acceleration of cholesterol efflux to high-density 
lipoproteins by the apoA-I binding protein (AIBP) interferes with the raft association 
of VEGFR2 and inhibits angiogenesis in vitro in HUVECs and in vivo in zebrafish 
(6). Moreover, blockade of cholesterol transport through endo-lysosomal 
compartments in HUVECs by the pharmaceuticals itraconazole, astemizole or 
cepharantine inhibits angiogenesis (5, 8, 38, 39). The present findings of ORP2 KD-
associated disturbances in cholesterol distribution in HUVECs are in agreement with 
these earlier observations. 
Of the ligands of ORP2, not only cholesterol plays a key role in angiogenesis, 
but also PI(4,5)P2, which we show to be enriched in the PM of ORP2-depleted 
HUVECs, is pivotal for the process. It acts as a substrate for phosphoinositide 3-
kinase (PI3K) and phospholipase C (PLC). PI3K plays central roles in angiogenesis 
via effectors such as Akt and FOXO (40-43), while PLC acts downstream of VEGF 
and is crucial for vasculogenesis (41, 44, 45). Of note, excess of PI(4,5)P2 at the 
endothelium has been reported to promote increased angiogenesis in vivo in zebrafish 
(46). 
 ORP2 was previously reported to promote cholesterol delivery to the PM in 
exchange for PI(4,5)P2 in HeLa cells (17). Consistently, we observed in HUVECs 
subjected to ORP2 KD an increase of PM PI(4,5)P2, whereas no significant reduction 
of PM total cholesterol content was detected, in apparent contradiction with the data 
of Wang et al. The reasons for this most likely lie in the use of different cell systems 
(HeLa vs. HUVECs) and different genetic manipulations (complete CRISPR-
mediated knock-out vs. partial KD by RNA interference). We do not find this 
surprising, since cholesterol is a major constituent of the PM, the homeostasis of 
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which is secured by multiple mechanisms which may vary between cell types and 
cancerous vs. primary cells (47, 48). Interference with ORP2 resulted in the 
accumulation of the D4H cholesterol probe in LE in both HeLa cells (16) and 
HUVECs (present study), which could indicate an altered organelle cholesterol 
concentration or reflect an altered organization of the cholesterol affecting its probe 
accessibility. It should also be noted that overexpression of ORP2 was earlier shown 
to enhance the transport of newly synthesized cholesterol from the ER to the PM (13). 
RNA sequencing of ORP2 KD HUVECs revealed a significant reduction in the 
expression of SREBP target genes, and parallel observations were made in the retina 
on Osbpl2
-/-
 mice, consistent with the view that ORP2 depletion may result in an 
elevation of cholesterol concentration in ER membranes harbouring the SREBP-
SCAP-INSIG apparatus (49, 50). The observations in this study do not allow us to 
state with certainty which specific step of inter-organelle cholesterol transport ORP2 
mediates in ECs.   
The present data demonstrate downstream signaling effects of ORP2 KD in 
several branches of the VEGF-VEGFR2 signaling network. In this context it is, 
however, important to notice that activity of the VEGFR2 downstream components 
analyzed, Akt, eNOS and p70S6K (mTOR target) is also sensitive to the availability 
of PM cholesterol (as this study demonstrates) and is reported to be regulated by their 
raft association (51-53). The suppression of their activity may thus also arise through 
mechanisms independent of VEGFR2 activity.  
A further clue to the mechanism through which ORP2 depletion impairs 
VEGFR2 function is provided by the observation of enhanced proteolytic cleavage of 
the receptor in HUVECs, yielding a residual 130-kDa receptor fragment that remains 
in the PM. This cleavage has been reported to mediate shedding of the receptor from 
the PM surface, resulting in its inactivation (54). Cell surface biotinylation in the 
present study confirmed that the cleavage in ORP2-depleted HUVECs occurs at the 
PM and is mediated by MMPs. Importantly, the VEGFR2 integrity seemed to be 
susceptible to the PM cholesterol composition, as similar MMP-mediated cleavage 
was seen in HUVECs with PM cholesterol depleted by using MCD. The impaired 
activating phosphorylation and enhanced proteolytic cleavage upon ORP2 KD may 
thus be due to a disturbance of the PM domain organization and the lateral 
distribution of VEGFR2, a notion supported by our observation that ORP2 KD shifts 
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VEGFR2 away from buoyant raft membranes. Of note, no significant reduction of 
total cellular VEGFR2 was observed in the ORP2 KD cells, but the effect was 
selective for the receptor pool biotinylated at the PM. 
We have previously shown that ORP2 knock-out in HuH7 hepatoma cells 
results in defective cell migration, proliferation and F-actin morphology (10), and 
impairs Akt activation, glucose metabolism and triglyceride synthesis (10, 11). There 
is also evidence for physical interactions of ORP2 with several F-actin regulatory 
proteins such as IQGAP1, Hsp90 and Cdc37, suggesting that the mechanisms of 
ORP2 action are not limited solely to inter-organelle lipid transport (10, 11, 15). The 
present observations on impaired HUVEC migration, proliferation and altered F-actin 
organization are in line with the previous findings in hepatoma cells (10). While these 
defects in ORP2-depleted cells could be in part due to loss of protein-protein 
interactions, they may also reflect defective lipid raft-dependent signaling or PIP 
homeostasis, especially since PI(4,5)P2 enriched in the PM of ORP2 KD cells plays a 
key role in cortical F-actin regulation (55, 56).  
The retinal phenotype of the Osbpl2
-/- 
animals suggests that, in apparent 
contrast to the HUVEC data, no physiologically significant inhibition of VEGFR2 
signaling is manifested in vivo, since such defects result in drastic disturbances of 
angiogenesis (57, 58). If the VEGFR2 signaling, nevertheless, is affected in the 
animals, this could be compensated in vivo by as yet undefined mechanisms, such as 
enhanced activity of VEGFR3, which has the capacity to sustain angiogenic sprouting 
and vascular network formation during development (57, 58). The increased density 
of tip cells and sprouts of the Osbpl2
-/- 
vasculature would be consistent with Notch 
signaling being affected (59, 60). The Notch pathway dampens the tip cell phenotype 
in stalk cells in the vicinity of an initial tip cell, thus allowing each tip cell to 
efficiently lead the growth of a branch, resulting in a normal vascular network 
structure (61). Of note, the organization of PM rafts is reported to affect Notch 
activity also independent of VEGF signaling (62). Despite the obvious inconsistently 
of the in vitro and in vivo observations concerning VEGFR2 signaling, gene 
expression analyses of the ORP2
-/-
 mouse retina revealed interesting parallels between 
the in vitro and in vivo data: The Cdh5 (VE-cadherin) mRNA was significantly 
reduced in the Osbpl2
-/-
 retina, similar to the HUVEC model, and the top cholesterol 
biosynthetic gene suppressed in the ORP2 KD HUVECs, Fdft1, as well as Srebp-2 
and mTOR were downregulated. Moreover, the Notch pathway genes Ccnd1, Dll1, 
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Jag1 and Stat1 were found suppressed in both the ORP2
-/-
 mice and the HUVEC 
subjected to ORP2 KD.  
VE-cadherin dynamics plays a crucial role in the inter-cellular contacts at 
which Notch signals are mediated (63-65). VE-cadherin is also reported to stabilize 
VEGFR2 (66), consistent with our observation of coincident VE-cadherin reduction 
and VEGFR2 cleavage. Moreover, depletion of VE-cadherin increases angiogenic 
sprouting (63, 67), in agreement with our data showing an increase of tip cells and 
perpendicular sprouts in ORP2
-/-
 retina. Puzzlingly, the retinal phenotype of the 
ORP2
-/-
 animals is very subtle, although the PM cholesterol organization is reported 
to have major effects on VEGF signaling and angiogenesis (3,5,6,8,31,32). A 
plausible explanation is the existence of several overlapping cholesterol trafficking 
routes from endosomes to the PM, such as a Rab8-myosin V-mediated vesicular 
pathway (68) and a recently described ORP1S-mediated pathway (69). Generation 
and characterization of an endothelial-specific knock-out of Osbpl2 in the future will 
be required to reach a detailed understanding of Osbpl2/ORP2 function in the biology 
of ECs.   
To conclude, the present work documents for the first time a function of an 
OSBP-related lipid transfer protein in angiogenesis. While the molecular details are as 
yet not completely understood, our data suggest that ORP2 activity is required for 
normal angiogenic signaling, the underlying mechanism most likely involving the 
impacts of ORP2 on the PM lipid composition and/or domain organization. The 
present work prompts further research to elucidate the functions of lipid transfer 
proteins in healthy ECs and in diseases involving endothelial dysfunction. 
 
ACKNOWLEDGMENTS 
We thank Prof. Gregory Fairn (Department of Biochemistry, University of Toronto, 
ON, Canada) for kindly providing the fluorescent D4H construct, Prof. Arun 
Radhakrishnan (Univ. of Texas Southwestern Medical Center, Dallas, TX) for kindly 
providing the purified His6-ALOD4 protein, Prof. Pipsa Saharinen (Faculty of 
Medicine, Univ. of Helsinki and the Wihuri Research Institute, Helsinki, Finland) for 
generous help and advice on the EC work, and Adj. prof. You Zhou (Cardiff 
University School of Medicine, Cardiff, UK) for kind support in pathway analysis. 
We also acknowledge the invaluable help of Biomedicum Imaging Unit (BIU; 
Helsinki Institute of Life Science, HiLIFE, and Biocenter Finland imaging 
 30 
infrastructure), the Biomedicum Functional Genomics Unit (FUGU; HiLIFE), and the 
Genome Biology Unit (GBU), part of the Genome Editing and Stem Cells 
(GoEditStem) core-unit platform and of the National Biocenter Finland Genome-wide 
methods network (GWM). This study was supported by grants from the Academy of 
Finland (grants 285223 and 322647 to V.M.O. and 282192 and 324929 to E.I.), the 
Sigrid Juselius Foundation, the Magnus Ehrnrooth Foundation, the Finnish 
Foundation for Cardiovascular Research (V.M.O.), the Leducq Foundation for 
Cardiovascular Research (E.I.), the Emil Aaltonen Foundation (A.Ko.), the Ida 
Montin Foundation (A.Ko.), the National Institutes of Health (R35GM122530 to 
W.C.) and the NSFC, China (grants 8170438 and 91439122 to D.Y.). The funding 
bodies played no role in the study design, analysis or interpretation of the data, 




A.Ko., G. P., A.Ki, R.K., A.A., J.T., A.R., O.K. and J.N. performed the experiments. 
A.Ko., A.Ki, A.A., E.I., W.C., D.Y. and V.M.O. designed the experiments and 
interpreted the results. A.Ko. and V.M.O wrote the manuscript and all authors 
commented on it. 
 
CONFLICT OF INTEREST 




1. Lingwood, D., and Simons, K. (2010) Lipid rafts as a membrane-organizing 
principle. Science 327, 46-50 
2. Anderson, R. G. (1998) The caveolae membrane system. Annu Rev Biochem 
67, 199-225 
3. Noghero, A., Perino, A., Seano, G., Saglio, E., Lo Sasso, G., Veglio, F., 
Primo, L., Hirsch, E., Bussolino, F., and Morello, F. (2012) Liver X receptor 
activation reduces angiogenesis by impairing lipid raft localization and 
 31 
signaling of vascular endothelial growth factor receptor-2. Arterioscler 
Thromb Vasc Biol 32, 2280-2288 
4. Zhu, L., and Fang, L. (2015) AIBP: A Novel Molecule at the Interface of 
Cholesterol Transport, Angiogenesis, and Atherosclerosis. Methodist Debakey 
Cardiovasc J 11, 160-165 
5. Lyu, J., Yang, E. J., Head, S. A., Ai, N., Zhang, B., Wu, C., Li, R. J., Liu, Y., 
Chakravarty, H., Zhang, S., Tam, K. Y., Dang, Y., Kwon, H. J., Ge, W., Liu, 
J. O., and Shim, J. S. (2018) Astemizole Inhibits mTOR Signaling and 
Angiogenesis by Blocking Cholesterol Trafficking. Int J Biol Sci 14, 1175-
1185 
6. Fang, L., Choi, S. H., Baek, J. S., Liu, C., Almazan, F., Ulrich, F., Wiesner, P., 
Taleb, A., Deer, E., Pattison, J., Torres-Vazquez, J., Li, A. C., and Miller, Y. I. 
(2013) Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature 
498, 118-122 
7. Cross, M. J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003) 
VEGF-receptor signal transduction. Trends Biochem Sci 28, 488-494 
8. Lyu, J., Yang, E. J., Head, S. A., Ai, N., Zhang, B., Wu, C., Li, R. J., Liu, Y., 
Yang, C., Dang, Y., Kwon, H. J., Ge, W., Liu, J. O., and Shim, J. S. (2017) 
Pharmacological blockade of cholesterol trafficking by cepharanthine in 
endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett 409, 
91-103 
9. Kentala, H., Weber-Boyvat, M., and Olkkonen, V. M. (2016) OSBP-Related 
Protein Family: Mediators of Lipid Transport and Signaling at Membrane 
Contact Sites. Int Rev Cell Mol Biol 321, 299-340 
10. Kentala, H., Koponen, A., Kivelä, A. M., Andrews, R., Li, C., Zhou, Y., and 
Olkkonen, V. M. (2018) Analysis of ORP2-knockout hepatocytes uncovers a 
novel function in actin cytoskeletal regulation. FASEB J 32, 1281-1295 
11. Kentala, H., Koponen, A., Vihinen, H., Pirhonen, J., Liebisch, G., Pataj, Z., 
Kivelä, A., Li, S., Karhinen, L., Jääskeläinen, E., Andrews, R., Meriläinen, L., 
Matysik, S., Ikonen, E., Zhou, Y., Jokitalo, E., and Olkkonen, V. M. (2018) 
OSBP-related protein-2 (ORP2): a novel Akt effector that controls cellular 
energy metabolism. Cell Mol Life Sci 75, 4041-4057 
12. Laitinen, S., Lehto, M., Lehtonen, S., Hyvärinen, K., Heino, S., Lehtonen, E., 
Ehnholm, C., Ikonen, E., and Olkkonen, V. M. (2002) ORP2, a homolog of 
 32 
oxysterol binding protein, regulates cellular cholesterol metabolism. J Lipid 
Res 43, 245-255 
13. Hynynen, R., Laitinen, S., Käkelä, R., Tanhuanpää, K., Lusa, S., Ehnholm, C., 
Somerharju, P., Ikonen, E., and Olkkonen, V. M. (2005) Overexpression of 
OSBP-related protein 2 (ORP2) induces changes in cellular cholesterol 
metabolism and enhances endocytosis. Biochem J 390, 273-283 
14. Zhang, C., Zhang, H., Zhang, M., Lin, C., Wang, H., Yao, J., Wei, Q., Lu, Y., 
Chen, Z., Xing, G., and Cao, X. (2019) OSBPL2 deficiency upregulate SQLE 
expression increasing intracellular cholesterol and cholesteryl ester by 
AMPK/SP1 and SREBF2 signalling pathway. Exp Cell Res 383, 111512 
15. Escajadillo, T., Wang, H., Li, L., Li, D., and Sewer, M. B. (2016) Oxysterol-
related-binding-protein related Protein-2 (ORP2) regulates cortisol 
biosynthesis and cholesterol homeostasis. Mol Cell Endocrinol 427, 73-85 
16. Koponen, A., Arora, A., Takahashi, K., Kentala, H., Kivela, A. M., 
Jaaskelainen, E., Peränen, J., Somerharju, P., Ikonen, E., Viitala, T., and 
Olkkonen, V. M. (2019) ORP2 interacts with phosphoinositides and controls 
the subcellular distribution of cholesterol. Biochimie 158, 90-101 
17. Wang, H., Ma, Q., Qi, Y., Dong, J., Du, X., Rae, J., Wang, J., Wu, W. F., 
Brown, A. J., Parton, R. G., Wu, J. W., and Yang, H. (2019) ORP2 Delivers 
Cholesterol to the Plasma Membrane in Exchange for Phosphatidylinositol 4, 
5-Bisphosphate (PI(4,5)P2). Mol Cell 73, 458-473 e457 
18. Weber-Boyvat, M., Kentala, H., Peränen, J., and Olkkonen, V. M. (2015) 
Ligand-dependent localization and function of ORP-VAP complexes at 
membrane contact sites. Cell Mol Life Sci 72, 1967-1987 
19. Sigoillot, F. D., Lyman, S., Huckins, J. F., Adamson, B., Chung, E., 
Quattrochi, B., and King, R. W. (2012) A bioinformatics method identifies 
prominent off-targeted transcripts in RNAi screens. Nat Methods 9, 363-366 
20. Yoon, Y., Lee, P. J., Kurilova, S., and Cho, W. (2011) In situ quantitative 
imaging of cellular lipids using molecular sensors. Nat Chem 3, 868-874 
21. Liu, S. L., Sheng, R., O'Connor, M. J., Cui, Y., Yoon, Y., Kurilova, S., Lee, 
D., and Cho, W. (2014) Simultaneous in situ quantification of two cellular 
lipid pools using orthogonal fluorescent sensors. Angew Chem Int Ed Engl 53, 
14387-14391 
 33 
22. Liu, S. L., Wang, Z. G., Hu, Y., Xin, Y., Singaram, I., Gorai, S., Zhou, X., 
Shim, Y., Min, J. H., Gong, L. W., Hay, N., Zhang, J., and Cho, W. (2018) 
Quantitative Lipid Imaging Reveals a New Signaling Function of 
Phosphatidylinositol-3,4-Bisphophate: Isoform- and Site-Specific Activation 
of Akt. Mol Cell 71, 1092-1104 e1095 
23. Endapally, S., Infante, R. E., and Radhakrishnan, A. (2019) Monitoring and 
Modulating Intracellular Cholesterol Trafficking Using ALOD4, a 
Cholesterol-Binding Protein. Methods Mol Biol 1949, 153-163 
24. Kallio, M. A., Tuimala, J. T., Hupponen, T., Klemelä, P., Gentile, M., 
Scheinin, I., Koski, M., Käki, J., and Korpelainen, E. I. (2011) Chipster: user-
friendly analysis software for microarray and other high-throughput data. 
BMC Genomics 12, 507 
25. Langmead, B., and Salzberg, S. L. (2012) Fast gapped-read alignment with 
Bowtie 2. Nat Methods 9, 357-359 
26. Anders, S., Pyl, P. T., and Huber, W. (2015) HTSeq--a Python framework to 
work with high-throughput sequencing data. Bioinformatics 31, 166-169 
27. Love, M. I., Huber, W., and Anders, S. (2014) Moderated estimation of fold 
change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 
28. Kamburov, A., Pentchev, K., Galicka, H., Wierling, C., Lehrach, H., and 
Herwig, R. (2011) ConsensusPathDB: toward a more complete picture of cell 
biology. Nucleic Acids Res 39, D712-717 
29. Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., and Mann, M. 
(2014) Accurate proteome-wide label-free quantification by delayed 
normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol 
Cell Proteomics 13, 2513-2526 
30. Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., 
Mann, M., and Cox, J. (2016) The Perseus computational platform for 
comprehensive analysis of (prote)omics data. Nat Methods 13, 731-740 
31. Mohamed, A., Shah, A. D., Chen, D., and Hill, M. M. (2019) RaftProt V2: 
understanding membrane microdomain function through lipid raft proteomes. 
Nucleic Acids Res 47, D459-D463 
32. Swendeman, S., Mendelson, K., Weskamp, G., Horiuchi, K., Deutsch, U., 
Scherle, P., Hooper, A., Rafii, S., and Blobel, C. P. (2008) VEGF-A stimulates 
 34 
ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 
and ERK signaling. Circ Res 103, 916-918 
33. Tellier, E., Canault, M., Rebsomen, L., Bonardo, B., Juhan-Vague, I., 
Nalbone, G., and Peiretti, F. (2006) The shedding activity of ADAM17 is 
sequestered in lipid rafts. Exp Cell Res 312, 3969-3980 
34. Matthews, V., Schuster, B., Schutze, S., Bussmeyer, I., Ludwig, A., 
Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K. J., and 
Rose-John, S. (2003) Cellular cholesterol depletion triggers shedding of the 
human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol 
Chem 278, 38829-38839 
35. Mungamuri, S. K., Yang, X., Thor, A. D., and Somasundaram, K. (2006) 
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-
dependent inhibition of p53. Cancer Res 66, 4715-4724 
36. Wang, B. T., Ducker, G. S., Barczak, A. J., Barbeau, R., Erle, D. J., and 
Shokat, K. M. (2011) The mammalian target of rapamycin regulates 
cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant 
transcriptional profile. Proc Natl Acad Sci U S A 108, 15201-15206 
37. Abhinand, C. S., Raju, R., Soumya, S. J., Arya, P. S., and Sudhakaran, P. R. 
(2016) VEGF-A/VEGFR2 signaling network in endothelial cells relevant to 
angiogenesis. J Cell Commun Signal 10, 347-354 
38. Xu, J., Dang, Y., Ren, Y. R., and Liu, J. O. (2010) Cholesterol trafficking is 
required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 
107, 4764-4769 
39. Head, S. A., Shi, W. Q., Yang, E. J., Nacev, B. A., Hong, S. Y., Pasunooti, K. 
K., Li, R. J., Shim, J. S., and Liu, J. O. (2017) Simultaneous Targeting of 
NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR 
Signaling and Angiogenesis. ACS Chem Biol 12, 174-182 
40. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., 
and Ferrara, N. (1998) Vascular endothelial growth factor regulates 
endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal 
transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 
273, 30336-30343 
 35 
41. Davies, E. M., Gurung, R., Le, K. Q., and Mitchell, C. A. (2019) Effective 
angiogenesis requires regulation of phosphoinositide signaling. Adv Biol Regul 
71, 69-78 
42. Im, E., and Kazlauskas, A. (2006) Regulating angiogenesis at the level of 
PtdIns-4,5-P2. EMBO J 25, 2075-2082 
43. Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., 
Yajima, N., Horie, Y., Hasegawa, G., Naito, M., Miyazaki, J., Suda, T., Itoh, 
H., Nakao, K., Mak, T. W., Nakano, T., and Suzuki, A. (2005) The 
PTEN/PI3K pathway governs normal vascular development and tumor 
angiogenesis. Genes Dev 19, 2054-2065 
44. Liao, H. J., Kume, T., McKay, C., Xu, M. J., Ihle, J. N., and Carpenter, G. 
(2002) Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. 
J Biol Chem 277, 9335-9341 
45. Lawson, N. D., Mugford, J. W., Diamond, B. A., and Weinstein, B. M. (2003) 
phospholipase C gamma-1 is required downstream of vascular endothelial 
growth factor during arterial development. Genes Dev 17, 1346-1351 
46. Pan, W., Pham, V. N., Stratman, A. N., Castranova, D., Kamei, M., Kidd, K. 
R., Lo, B. D., Shaw, K. M., Torres-Vazquez, J., Mikelis, C. M., Gutkind, J. S., 
Davis, G. E., and Weinstein, B. M. (2012) CDP-diacylglycerol synthetase-
controlled phosphoinositide availability limits VEGFA signaling and vascular 
morphogenesis. Blood 120, 489-498 
47. Mesmin, B., and Maxfield, F. R. (2009) Intracellular sterol dynamics. Biochim 
Biophys Acta 1791, 636-645 
48. Ikonen, E. (2018) Mechanisms of cellular cholesterol compartmentalization: 
recent insights. Curr Opin Cell Biol 53, 77-83 
49. Brown, M. S., and Goldstein, J. L. (1997) The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription 
factor. Cell 89, 331-340 
50. Chang, T. Y., Chang, C. C., Ohgami, N., and Yamauchi, Y. (2006) 
Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 22, 
129-157 
51. Lai, C. J., Cheng, H. C., Lin, C. Y., Huang, S. H., Chen, T. H., Chung, C. J., 
Chang, C. H., Wang, H. D., and Chuu, C. P. (2017) Activation of liver X 
 36 
receptor suppresses angiogenesis via induction of ApoD. FASEB J 31, 5568-
5576 
52. Calay, D., Vind-Kezunovic, D., Frankart, A., Lambert, S., Poumay, Y., and 
Gniadecki, R. (2010) Inhibition of Akt signaling by exclusion from lipid rafts 
in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 
1136-1145 
53. Tran, J., Magenau, A., Rodriguez, M., Rentero, C., Royo, T., Enrich, C., 
Thomas, S. R., Grewal, T., and Gaus, K. (2016) Activation of Endothelial 
Nitric Oxide (eNOS) Occurs through Different Membrane Domains in 
Endothelial Cells. PLoS One 11, e0151556 
54. Basagiannis, D., and Christoforidis, S. (2016) Constitutive Endocytosis of 
VEGFR2 Protects the Receptor against Shedding. J Biol Chem 291, 16892-
16903 
55. Hilpelä, P., Vartiainen, M. K., and Lappalainen, P. (2004) Regulation of the 
actin cytoskeleton by PI(4,5)P2 and PI(3,4,5)P3. Curr Top Microbiol Immunol 
282, 117-163 
56. Zhang, L., Mao, Y. S., Janmey, P. A., and Yin, H. L. (2012) 
Phosphatidylinositol 4, 5 bisphosphate and the actin cytoskeleton. Subcell 
Biochem 59, 177-215 
57. Benedito, R., Rocha, S. F., Woeste, M., Zamykal, M., Radtke, F., Casanovas, 
O., Duarte, A., Pytowski, B., and Adams, R. H. (2012) Notch-dependent 
VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 
signalling. Nature 484, 110-114 
58. Zarkada, G., Heinolainen, K., Makinen, T., Kubota, Y., and Alitalo, K. (2015) 
VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc Natl 
Acad Sci U S A 112, 761-766 
59. Suchting, S., Freitas, C., le Noble, F., Benedito, R., Breant, C., Duarte, A., and 
Eichmann, A. (2007) The Notch ligand Delta-like 4 negatively regulates 
endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 
104, 3225-3230 
60. Hellström, M., Phng, L. K., Hofmann, J. J., Wallgard, E., Coultas, L., 
Lindblom, P., Alva, J., Nilsson, A. K., Karlsson, L., Gaiano, N., Yoon, K., 
Rossant, J., Iruela-Arispe, M. L., Kalen, M., Gerhardt, H., and Betsholtz, C. 
 37 
(2007) Dll4 signalling through Notch1 regulates formation of tip cells during 
angiogenesis. Nature 445, 776-780 
61. Potente, M., and Carmeliet, P. (2017) The Link Between Angiogenesis and 
Endothelial Metabolism. Annu Rev Physiol 79, 43-66 
62. Mao, R., Meng, S., Gu, Q., Araujo-Gutierrez, R., Kumar, S., Yan, Q., 
Almazan, F., Youker, K. A., Fu, Y., Pownall, H. J., Cooke, J. P., Miller, Y. I., 
and Fang, L. (2017) AIBP Limits Angiogenesis Through gamma-Secretase-
Mediated Upregulation of Notch Signaling. Circ Res 120, 1727-1739 
63. Gaengel, K., Niaudet, C., Hagikura, K., Lavina, B., Muhl, L., Hofmann, J. J., 
Ebarasi, L., Nystrom, S., Rymo, S., Chen, L. L., Pang, M. F., Jin, Y., 
Raschperger, E., Roswall, P., Schulte, D., Benedito, R., Larsson, J., Hellstrom, 
M., Fuxe, J., Uhlen, P., Adams, R., Jakobsson, L., Majumdar, A., Vestweber, 
D., Uv, A., and Betsholtz, C. (2012) The sphingosine-1-phosphate receptor 
S1PR1 restricts sprouting angiogenesis by regulating the interplay between 
VE-cadherin and VEGFR2. Dev Cell 23, 587-599 
64. Bentley, K., Franco, C. A., Philippides, A., Blanco, R., Dierkes, M., Gebala, 
V., Stanchi, F., Jones, M., Aspalter, I. M., Cagna, G., Westrom, S., Claesson-
Welsh, L., Vestweber, D., and Gerhardt, H. (2014) The role of differential 
VE-cadherin dynamics in cell rearrangement during angiogenesis. Nat Cell 
Biol 16, 309-321 
65. Yamamoto, H., Ehling, M., Kato, K., Kanai, K., van Lessen, M., Frye, M., 
Zeuschner, D., Nakayama, M., Vestweber, D., and Adams, R. H. (2015) 
Integrin beta1 controls VE-cadherin localization and blood vessel stability. 
Nat Commun 6, 6429 
66. Calera, M. R., Venkatakrishnan, A., and Kazlauskas, A. (2004) VE-cadherin 
increases the half-life of VEGF receptor 2. Exp Cell Res 300, 248-256 
67. Abraham, S., Yeo, M., Montero-Balaguer, M., Paterson, H., Dejana, E., 
Marshall, C. J., and Mavria, G. (2009) VE-Cadherin-mediated cell-cell 
interaction suppresses sprouting via signaling to MLC2 phosphorylation. Curr 
Biol 19, 668-674 
68. Kanerva, K., Uronen, R. L., Blom, T., Li, S., Bittman, R., Lappalainen, P., 
Peränen, J., Raposo, G., and Ikonen, E. (2013) LDL cholesterol recycles to the 
plasma membrane via a Rab8a-Myosin5b-actin-dependent membrane 
transport route. Dev Cell 27, 249-262 
 38 
69. Zhao, K., Foster, J., and Ridgway, N. D. (2020) Oxysterol-binding protein-
related protein 1 variants have opposing cholesterol transport activities from 






Table 1. Angiogenic signaling pathways affected in the transcriptome of ORP2 
knock-down HUVECs (RNAseq), and in the peptide IDs of ORP2 interactome (MS) 
predicted by ConsensusPathDB pathway tool. Pathway databases included in the 
analysis: Wikipathways, KEGG, Reactome and PID (full lists of significant pathways 
in ORP2 KD RNAseq and ORP2-2xStrep mass spectrometric data are available upon 
request from the authors).   
 




   
 
 
  (%) 
Identical 













VEGF-VEGFR2 signaling(37) 181/236 (76.7) 24/236 (10.2) 2.82-18 1.65-08 
 Cell migration 78/103 (75.7) 9/103 (8.7) - - 
 Cell proliferation 52/70 (74.3) 7/70 (10.0) - - 
 Cell survival 68/94 (72.3) 10/94 (10.6) - - 
 VEGFR endocytosis  
and recycling 
23/30 (76.7) 9/30 (30.0) - - 
Rho GTPase signaling 277/435 (63.7) 19/435 (4.4) 9.02-11 2.05-02 
TGF-β signaling 101/132 (76.5) 10/132 (7.6) 1.09-10 2.66-03 
EGF-EGFR signaling  117/162 (72.2) 9/162 (5.6) 1.94-09 2.85-02 
Signaling by Hedgehog 84/96 (87.5) - - 3.23-08 - 
Signaling by RTKs 262/423 (61.9) 23/423 (5.4) 6.89-08 8.97-04 
TNF-α signaling 71/93 (76.3) - - 7.58-08 - 
PDGFR-β signaling 92/127 (72.4) 14/127 (11.0) 8.07-08 6.63-06 
FAK signaling 131/198 (66.2) 19/198 (9.6) 9.99-07 2.58-09 
Notch signaling 61/79  (77.2) - - 1.36-07 - 
JAK-STAT signaling 75/106  (70.8) - - 5.42-06 - 
mTOR signaling  49/65  (75.8) - - 6.96-06 - 
Cdc42 signaling 53/71 (74.7) - - 1.09-05 - 
PI3K/Akt signaling  29/35  (82.9) 19/353 (4.3) 4.05-05 2.76-03 
HIF-1-α signaling  48/66  (72.7) 5/66 (7.6) 8.75-05 3.03-02 
EPH-Ephrin signaling 52/74 (70.3) 9/74 (12.2) 1.95-04 1.40-04 





Table 2. Angiogenic cellular functions affected in the transcriptome of ORP2 knock-
down HUVECs (RNAseq), and the peptide IDs of ORP2 interactome (MS) predicted 
by ConsensusPathDB gene ontology (GO) analysis tool (full lists of significant GO 
terms in ORP2 KD RNAseq and ORP2-2xStrep mass spectrometric data are available 
upon request from the authors).   
 






Angiogenesis GO:0001525 1.44-16 1.06-03 
 Cardiovascular system development GO:0072358 8.06-21 9.55-04 
 Circulatory system development GO:0072359 3.12-20 2.07-03 
 Vasculature development GO:0001944 4.21-20 7.87-04 
 Blood vessel development GO:0001568 4.53-19 4.18-04 
 Tube morphogenesis GO:0035239 4.25-16 7.89-03 
 Blood vessel morphogenesis GO:0048514 5.64-16 3.50-03 
 Tube development GO:0035295 8.90-14 5.76-04 
 Regulation of vasculature development GO:1901342 2.16-09 - 
 Regulation of angiogenesis GO:0045765 1.05-08 3.06-02 
 Sprouting angiogenesis GO:0002040 3.54-08 8.96-03 
 Response to hypoxia GO:0001666 1.47-06 1.04-02 
 Tube closure GO:0060606 9.03-05 - 
 Blood vessel remodeling GO:0001974 4.66-04 - 
 Vasculogenesis GO:0001570 1.02-03 4.13-03 







Table 3. Cholesterol homeostasis-related cellular functions affected in the 
transcriptome of ORP2 knock-down HUVECs (RNAseq), and the peptide IDs of 
ORP2 interactome (MS) predicted by ConsensusPathDB gene ontology (GO) analysis 
tool (full lists of significant GO terms in ORP2 KD RNAseq and ORP2-2xStrep mass 
spectrometric data are available upon request from the authors). 
  






Lipid metabolic process GO:0006629 4.33-09 6.39-06 
 Sterol biosynthetic process GO:0016126 1.45-07 1.18-05 
 Regulation of cholesterol metabolic process GO:0090181 2.91-06 1.31-04 
 LDL particle clearance GO:0034383 2.02-03 3.73-06 
 Cholesterol metabolic process GO:0008203 3.18-05 9.98-07 
 Sterol metabolic process GO:0016125 2.82-04 4.23-06 
 Steroid biosynthetic process GO:0006694 5.69-03 1.12-04 
 Cholesterol storage GO:0010878 7.31-03 - 
 Phosphatidylinositol-mediated signaling GO:0048015 7.71-03 - 
 Steroid metabolic process GO:0008202 - 6.96-06 
Plasma membrane organization GO:0007009 6.87-03 1.70-05 
 Membrane raft organization  GO:0031579 - 5.17-05 
 Membrane raft assembly GO:0001765 1.90-03 4.88-05 






Figure 1. ORP2 KD accumulates D4H-accessible cholesterol in late endosomes (LE) 
and ORP2 overexpression transfers it towards the plasma membrane (PM) in 
HUVECs. (A) Localization of the mCherry-D4H cholesterol probe in CTRL siRNA 
expressing HUVECs compared to ORP2 siRNA expressing HUVECs. Anti-LAMP1 
was used as a LE marker and detected with Alexa488-conjugated secondary antibody. 
Nuclei were stained with Dapi. (B) Quantification of the mCherry-D4H probe LE and 
PM accumulation in ORP2 or CTRL siRNA expressing HUVECs. (C) Fluorescence 
microscopy images of the localization of the mCherry-D4H cholesterol probe, and 
(D) quantification of the LE and PM accumulation of the D4H probe in pEGFP-C1 
control plasmid, ORP2(wt)-pEGFP-C1, ORP2(mHHK)-pEGFP-C1 or ORP2ELSK-
pEGFP-C1 transfected HUVECs. The distribution of the D4H probe to LEs or PM is 
expressed as percentage of all analyzed D4H expressing cells. Approximately 100 
cells with equal expression levels of the transfected constructs were analyzed for each 
transfection (n=3). The statistical significance (Student’s t-test) is defined in 
comparison to control as ns, not significant, * p<0.05, ** p<0.01, *** p<0.001. Error 
bars represent ± SD. 
 
Figure 2. Impacts of ORP2 knock-down (KD) on plasma membrane (PM) cholesterol 
and PI(4,5)P2 content. (A) Relative PM cholesterol content in control (shC) and ORP2 
KD (shO2) HUVECs measured from isolated PM preparations by Amplex Red assay. 
(B) Representative western blot of PM-association of growing concentrations (0 µM, 
3 µM and 10 µM) of His6-ALOD4 cholesterol probe in control cells, ORP2 KD cells, 
and cells depleted of PM cholesterol by 30-min by methyl--cyclodextrin (MCD) 
treatment. (C) In situ quantification of PI(4,5)P2 at the PM of control and ORP2 KD 
HUVECs. The images show spatially resolved PI(4,5)P2 concentration in the cross-
section of a representative cell at a timepoint 0. A pseudo-coloring scheme with red 
representing the highest and blue the lowest concentration is used to illustrate the 
spatial concentration heterogeneity. Similar spatially heterogenous distribution was 
observed at different time points. Scale bars represent 10 μm. (D) Relative PM 
PI(4,5)P2 content of control and ORP2 KD cells measured from isolated PM 
preparations by competitive PI(4,5)P2 ELISA. The statistical significance (Student’s t-
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test) is defined in comparison to control as ns, not significant, * p<0.05, ** p<0.01, 
*** p<0.001. Error bars represent ± SD. 
 
Figure 3. Impacts of ORP2 manipulation on HUVEC protrusion and angiogenic 
network formation. (A) Representative images of protrusion formation in ORP2(wt)-
pEGFP-C1 expressing HUVECs as compared to pEGFP-C1 control plasmid 
expressing HUVECs in basal cell culture conditions. (B) Quantification of HUVEC 
protrusion formation shown as percentage of transfected cells with prominent 
protrusions in ORP2(wt)- pEGFP-C1, ORP2(mHHK)-pEGFP-C1 and 
ORP2(ELSK)-pEGFP-C1 overexpressing cells in basal cell culture conditions. 
Empty plasmid (pEGFP-C1) was used as a control. For each transfection ≥ 100 cells 
were analyzed (n=3). (C) Representative images of angiogenic tubular network in 
lentivirally silenced control HUVECs (shCTRL) ORP2 knock-down (shORP2) 
HUVECs in the absence or presence of treatment with methyl--cyclodextrin-
cholesterol complexes (+ chol). Images were taken 5 hours after cell seeding on 
matrix, with 4x magnification and analyzed with Angiogenesis Analyzer plugin of 
ImageJ (overlay of analysis shown in black) (D) Quantification of angiogenic tube 
formation parameters: number of tubular nodes, junctions, meshes, segments and 
branches, and total branching length in the absence (-) or presence (+) of 3-hour 
treatment with methyl--cyclodextrin-cholesterol complexes. The statistical 
significance (Student’s t-test) is defined in comparison to control as ns, not 
significant, * p<0.05, ** p<0.01, *** p<0.001. Error bars represent ± SD. 
 
Figure 4. ORP2 knock-down attenuates the activity of several angiogenic regulatory 
proteins and reduces the expression of PM lipid raft-associated proteins Caveolin-1 
and VE-cadherin. (A) Western blot analysis of VEGFR2 phosphorylation in shCTRL 
(shC) and shORP2 (shO2) lentivirus-transduced HUVECs after 0-, 3- and 12-min 
treatment with VEGF-A165. (B) Representative western blots and quantification of 
VEGFR2, Akt, eNOS3 and p70S6K phosphorylation upon 12-min VEGF-A165 
stimulus in shORP2 and shCTRL expressing HUVECs (n ≥ 3). (C) Representative 
western blots of VEGFR2, Akt, eNOS3 and p70S6K phosphorylation upon 12-min 
VEGF-A165 stimulus in naïve (-) and cholesterol-depleted (+) HUVECs. tot = total 
protein, p = phosphorylated protein. Lanes showing the total protein on the western 
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filters are shown in Supplementary Fig. S2B,C. (D) The expression of Caveolin-1 and 
VE-cadherin quantified from shORP2 and shCTRL total cell lysate western blots (n ≥ 
3). (E) The expression of Flotillin-1 and Annexin A2 detected from shCTRL (shC) 
and shORP2 (shO2) total cell lysates by western blotting. The statistical significance 
(Student’s t-test) is defined in comparison to shCTRL as * p<0.05, ** p<0.01, 
*** p<0.001. Error bars represent ± SD. 
 
Figure 5. ORP2 knock-down impairs several angiogenic cell functions. (A) 
Representative proliferation graphs of ORP2 knock-down (shORP2) HUVECs 
compared to control (shCTRL) HUVECs. The cells were seeded as a sub-confluent 
monolayer on an xCELLigence® microelectrode biosensor and monitored in real-
time for 20 h. (B) Viability of shORP2 HUVECs compared to shCTRL HUVECs 
determined by MTT assay performed on a confluent monolayer 12-h incubation with 
VEGF-A165. Data is from four independent experiment each performed in five parallel 
wells. (C) Representative images of wound closure of ORP2 KD HUVECs compared 
to CTRL HUVECs plated on fibronectin-gelatin-coated 96-well plates, wounded with 
an IncuCyte® Wound Maker, and imaged before and after a 24-h incubation in 
IncuCyte ZOOM® system in basal growth media (D) Representative wound closure 
graphs of shORP2 and shCTRL HUVECs incubated for 20 hours and analyzed by 
IncuCyte ZOOM® automated quantification system (E). Representative curves of 
growth-factor stimulated trans-filter migration of shORP2 HUVECs compared to 
shCTRL HUVEs measured in real-time with xCELLigence® cell impedance-based 
migration application. (F) Representative images of shORP2 and shCTRL cell 
morphology imaged with Evos XL Cell Imaging System. (G) Representative images 
of the actin cytoskeleton organization and focal adhesion assembly in shORP2 
HUVECs as compared to shCTRL HUVECs identified by phalloidin and p-paxillin 
immunofluorescence staining. The statistical significance (Student’s t-test) is defined 
in comparison to shCTRL as * p<0.05, ** p<0.01, *** p<0.001. Error bars represent ± 
SD. 
 
Figure 6. ORP2 knock-down decreases compartmentation of VEGFR2 into plasma 
membrane (PM) lipid rafts, reduces lipid raft-associated cholesterol and increases 
VEGFR2 cleavage at the PM of HUVECs. (A) Representative western blots of 
detergent-free cell fractionation of shCTRL and shORP2 HUVECs. The distributions 
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of VEGFR2, Flotillin-1 and -tubulin are shown. Fraction 4 represents buoyant lipid 
raft membranes, fractions 5 & 6 heavier membranes, and fractions 8 & 9 the cytosol. 
(B) Quantification of the relative abundance of VEGFR2 in the lipid raft membrane 
fraction (Fr.4) of shCTRL and shORP2 HUVECs. (C) Quantification of the relative 
cholesterol content in the lipid raft membrane fraction (Fr.4) and in the heavier 
membrane fractions (Fr. 5 & 6) of shCTRL and shORP2 HUVECs. (D) ORP2 was 
knocked down in HUVECs by lentiviral transduction and the PM receptors were 
isolated by cell surface biotinylation and NeutrAvidin pull-down. Full-length 
VEGFR2 (230 kDa) and its cleaved form (130 kDa) were identified with anti-
VEGFR2 antibody by western blotting. Tot. = total amount of VEGFR2 in cell 
lysates, PM = PM pool of VEGFR2 isolated by NeutrAvidin pull-down, int. = 
intracellular pool of VEGFR2 (remaining sample after NeutrAvidin pull-down). (E) 
Quantification of the cleaved 130 kDa residue of VEGFR2 at the PM of shORP2 and 
shCTRL HUVECs as percentages of the total PM pool of VEGFR2 (130 kDa + 230 
kDa). (F) PM pool of full-length (230 kDa) and cleaved (130 kDa) VEGFR2 in 
control and ORP2 KD cells in the absence (-) or presence (+) of o/n treatment with 5 
µM MMPi Marimastat. (G) PM pool of full-length (230 kDa) and cleaved (130 kDa) 
VEGFR2 in control (CTRL) and ORP2(wt) (oexO2) lentivirus transduced HUVECs. 
(H) Left; PM pool of full-length and cleaved form of VEGFR2 in cells depleted of 
PM cholesterol by 0-min, 30-min or 60-min methyl--cyclodextrin treatment 
(MCD). Right; The PM pool of full-length (230 kDa) and cleaved (130 kDa) 
VEGFR2 in cells depleted of PM cholesterol by 30-min MCD incubation in the 
absence (-) or presence (+) of o/n treatment with 5 µM MMPi Marimastat. The 
statistical significance (Student’s t-test) is defined in comparison to shCTRL as * 
p<0.05, ** p<0.01, *** p<0.001. Error bars represent ± SD. 
 
Figure 7. Loss of ORP2 results in dysregulation of retinal angiogenesis. Retinas from 
control (WT) and ORP2 knock out (ORP2
-/-
) P7 littermate pups were analyzed by 
isolectin B4 immunostaining. (A) Confocal images of two different levels (1, 2) of 
retinas are shown as indicated. The superficial vascular plexus (1) is morphologically 
altered, and the extension of perpendicular endothelial sprouts (2) is significantly 
enhanced in ORP2
-/- 
pup retinas. Bars, 200 μm. (B, C) The quantification of vessel 
length, endothelial cell (EC) area/field, branch points and perpendicular endothelial 
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sprouts in front and central areas of the control (WT) and ORP2 KO (ORP2
-/-
) retinas 
from confocal microscopy images. The perpendicular sprouts were imaged form a 
focal plane underneath the vascular plexus. (C) Isolectin B4 immunofluorescence 
staining and tip cell quantification showing increased tip cell and filopodia extension 
at the angiogenic front of the ORP2
-/- 
P7 pup retinas. Bars, 100 μm. (D) qPCR 
quantification of the Notch pathway mRNAs encoding cyclin D1 (CCND1), Delta-
like protein 1 (DLL1), Jagged 1 (JAG1) and signal transducer and activator of 
transcription 1 (STAT1), mRNAs encoding cholesterol homeostatic components 
Farnesyl-Diphosphate Farnesyltransferase 1 (FDFT1) and Sterol Regulatory Element 
Binding Transcription Factor 2 (SREBF2) as well as mRNAs of cell-cell contact 
regulating VE-cadherin (CDH5) and a nod involved in Notch and VEGF signaling 
and in cholesterol biosynthesis, Mammalian Target Of Rapamycin (mTOR).  The 
statistical significance (Student’s t-test) is defined as ns, not significant, * p<0.05, 














Supplementary Table S1. List of the antibodies used  
Antibody (anti-) Source  Type  Manufacturer Catalogue number  
Akt  rabbit  polyclonal  Cell Signaling 9272 
Annexin A2  rabbit  polyclonal  Abcam ab178677 
Caveolin-1 (clone 2297) mouse  monoclonal  BD Transduction laboratories 610406 
eNOS3 rabbit  polyclonal Abcam ab5589 
ERK1/2 rabbit  polyclonal  Cell Signaling 9102 
FAK (clone D-1) mouse  monoclonal  Santa Cruz Biotechnology  sc-271126 
Flotillin-1  rabbit  polyclonal Cell Signaling 3253 
GFP rabbit  polyclonal Molecular Probes A-6455 
His6 mouse monoclonal ABclonal AE003 
LAMP1 (clone H4A3) mouse  monoclonal  Santa Cruz Biotechnology  sc-20011 
ORP2  rabbit  polyclonal Novus Biologicals  92236 
p70S6K rabbit  polyclonal Cell Signaling 9202 
phospho-Akt(Ser473) rabbit  polyclonal  Cell Signaling 9271 
phospho-eNOS3(Ser1177) rabbit  polyclonal  Cell Signaling 9571 
phospho-
ERK1/2(Thr202/Tyr204) 
mouse  monoclonal  Cell Signaling 9106 
phospho-FAK(Tyr397) rabbit  monoclonal  Santa Cruz Biotechnology  8556T 
phospho-p70S6K(Thr398) rabbit  polyclonal  Cell Signaling 9205 
phospho-Paxillin(Tyr118)  rabbit  polyclonal  Santa Cruz Biotechnology  sc-14036-R 
phospho-VEGFR2(Tyr1175) rabbit  monoclonal  Cell Signaling 2478 
VE-cadherin (clone 123413) mouse  monoclonal  R&D Systems MAB9381-SP 
VEGFR2 (clone 55B11) rabbit  monoclonal  Cell Signaling 2479 
β-actin  rabbit  polyclonal  Sigma-Aldrich A2066 
β-tubulin (clone AA2) mouse monoclonal Merck 05-661 
 
Supplementary Table S2. Cellular functions downstream of VEGF signaling associated with 
mRNAs of ORP2 knock-down HUVECs (RNAseq) and peptide IDs of ORP2 interactome (MS) 
predicted by ConsensusPath gene onthology (GO) analysis tool. (full lists of significant GO terms 
in ORP2 KD RNAseq and ORP2-2xStrep mass spectrometric data are available upon request from 
the authors)  
 
















 Regulation of cell cycle  GO:0051726 1.27
-26
 - 





 Regulation of cell proliferation GO:0042127 1.61
-11
 - 
 Cell growth GO:0016049 1.97
-09
 - 




















 Microtubule cytoskeleton organization GO:0000226 1.24
-07
 - 


















































 Regulation of endothelial cell migration GO:0010594 5.15
-10
 - 

















































Supplementary Table S3. Significantly affected gene IDs of SREBP1 signaling pathway in ORP2 KD HUVECs. SREPB1 signaling pathway from 
WikiPathways database was used as a reference (described in Daemen, Kutmon & Evelo 2013: https://doi.org/10.1007/s12263-013-0342-x). Only 
pathways with p-value 0.05 are included.  
 
Symbol Description log2FoldChange p-adj. 
MTOR mechanistic target of rapamycin kinase [Source:HGNC Symbol;Acc:HGNC:3942] -1.11 4.03E-162 
FDFT1 farnesyl-diphosphate farnesyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:3629] -0.93 7.01E-131 
MED15 mediator complex subunit 15 [Source:HGNC Symbol;Acc:HGNC:14248] 0.76 3.77E-101 
SAR1B secretion associated Ras related GTPase 1B [Source:HGNC Symbol;Acc:HGNC:10535] 0.88 1.08E-71 
INSIG1 insulin induced gene 1 [Source:HGNC Symbol;Acc:HGNC:6083] -0.94 2.04E-66 
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 [Source:HGNC Symbol;Acc:HGNC:5007] -0.79 6.42E-65 
LSS lanosterol synthase [Source:HGNC Symbol;Acc:HGNC:6708] -0.7 1.36E-56 
DBI diazepam binding inhibitor. acyl-CoA binding protein [Source:HGNC Symbol;Acc:HGNC:2690] -0.62 7.62E-47 
SEC24C SEC24 homolog C. COPII coat complex component [Source:HGNC Symbol;Acc:HGNC:10705] 0.42 1.10E-45 
LDLR low density lipoprotein receptor [Source:HGNC Symbol;Acc:HGNC:6547] 0.68 2.88E-43 
SREBF2 sterol regulatory element binding transcription factor 2 [Source:HGNC Symbol;Acc:HGNC:11290] -0.5 2.84E-39 
FASN fatty acid synthase [Source:HGNC Symbol;Acc:HGNC:3594] -0.51 1.87E-36 
IDI1 isopentenyl-diphosphate delta isomerase 1 [Source:HGNC Symbol;Acc:HGNC:5387] -0.62 1.11E-34 
SQLE squalene epoxidase [Source:HGNC Symbol;Acc:HGNC:11279] -0.56 4.89E-32 
MVD mevalonate diphosphate decarboxylase [Source:HGNC Symbol;Acc:HGNC:7529] -0.67 2.74E-30 
PRKAB2 protein kinase AMP-activated non-catalytic subunit beta 2 [Source:HGNC Symbol;Acc:HGNC:9379] 0.51 2.84E-28 
SCD stearoyl-CoA desaturase [Source:HGNC Symbol;Acc:HGNC:10571] -0.54 2.19E-25 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase [Source:HGNC Symbol;Acc:HGNC:5006] -0.38 5.64E-23 
PRKAG1 protein kinase AMP-activated non-catalytic subunit gamma 1 [Source:HGNC Symbol;Acc:HGNC:9385] -0.51 2.32E-21 
SEC31A SEC31 homolog A. COPII coat complex component [Source:HGNC Symbol;Acc:HGNC:17052] 0.31 2.77E-21 
SEC13 
SEC13 homolog. nuclear pore and COPII coat complex component [Source:HGNC 
Symbol;Acc:HGNC:10697] 0.28 1.68E-19 
FDPS farnesyl diphosphate synthase [Source:HGNC Symbol;Acc:HGNC:3631] -0.25 2.04E-17 
SCARB1 scavenger receptor class B member 1 [Source:HGNC Symbol;Acc:HGNC:1664] -0.32 1.47E-16 
NR1H2 nuclear receptor subfamily 1 group H member 2 [Source:HGNC Symbol;Acc:HGNC:7965] 0.27 1.51E-13 
SEC23B Sec23 homolog B. coat complex II component [Source:HGNC Symbol;Acc:HGNC:10702] 0.32 6.14E-13 
ACSS1 acyl-CoA synthetase short chain family member 1 [Source:HGNC Symbol;Acc:HGNC:16091] -0.63 1.44E-12 
PIK3CA 
phosphatidylinositol-4.5-bisphosphate 3-kinase catalytic subunit alpha [Source:HGNC 
Symbol;Acc:HGNC:8975] 0.32 5.12E-12 
PRKAA1 protein kinase AMP-activated catalytic subunit alpha 1 [Source:HGNC Symbol;Acc:HGNC:9376] -0.28 1.34E-11 
ACLY ATP citrate lyase [Source:HGNC Symbol;Acc:HGNC:115] -0.23 2.13E-11 
ACACA acetyl-CoA carboxylase alpha [Source:HGNC Symbol;Acc:HGNC:84] -0.3 2.63E-11 
PRKACA protein kinase cAMP-activated catalytic subunit alpha [Source:HGNC Symbol;Acc:HGNC:9380] -0.26 1.06E-10 
ATF6 activating transcription factor 6 [Source:HGNC Symbol;Acc:HGNC:791] 0.24 1.24E-10 
SEC24D SEC24 homolog D. COPII coat complex component [Source:HGNC Symbol;Acc:HGNC:10706] 0.24 1.86E-10 
INSIG2 insulin induced gene 2 [Source:HGNC Symbol;Acc:HGNC:20452] -0.32 2.44E-08 
NFYA nuclear transcription factor Y subunit alpha [Source:HGNC Symbol;Acc:HGNC:7804] -0.25 5.74E-08 
MBTPS2 membrane bound transcription factor peptidase. site 2 [Source:HGNC Symbol;Acc:HGNC:15455] 0.3 7.54E-08 
MBTPS1 membrane bound transcription factor peptidase. site 1 [Source:HGNC Symbol;Acc:HGNC:15456] 0.19 1.05E-07 
PPARGC1B PPARG coactivator 1 beta [Source:HGNC Symbol;Acc:HGNC:30022] 0.5 5.88E-07 
PRKAB1 protein kinase AMP-activated non-catalytic subunit beta 1 [Source:HGNC Symbol;Acc:HGNC:9378] 0.27 2.45E-06 
LPIN1 lipin 1 [Source:HGNC Symbol;Acc:HGNC:13345] -0.19 5.76E-06 
SP1 Sp1 transcription factor [Source:HGNC Symbol;Acc:HGNC:11205] -0.21 3.93E-05 
KPNB1 karyopherin subunit beta 1 [Source:HGNC Symbol;Acc:HGNC:6400] -0.16 5.08E-05 
SAR1A secretion associated Ras related GTPase 1A [Source:HGNC Symbol;Acc:HGNC:10534] -0.15 9.02E-05 
CYP51A1 cytochrome P450 family 51 subfamily A member 1 [Source:HGNC Symbol;Acc:HGNC:2649] -0.38 6.24E-04 
SEC24A SEC24 homolog A. COPII coat complex component [Source:HGNC Symbol;Acc:HGNC:10703] -0.15 8.66E-04 
AMFR autocrine motility factor receptor [Source:HGNC Symbol;Acc:HGNC:463] 0.12 2.05E-03 
AKT1S1 AKT1 substrate 1 [Source:HGNC Symbol;Acc:HGNC:28426] 0.1 3.27E-03 
PRKAA2 protein kinase AMP-activated catalytic subunit alpha 2 [Source:HGNC Symbol;Acc:HGNC:9377] 0.32 9.04E-03 
RNF139 ring finger protein 139 [Source:HGNC Symbol;Acc:HGNC:17023] 0.15 1.06E-02 
CDK8 cyclin dependent kinase 8 [Source:HGNC Symbol;Acc:HGNC:1779] -0.16 1.16E-02 
YY1 YY1 transcription factor [Source:HGNC Symbol;Acc:HGNC:12856] -0.1 1.85E-02 
GSK3A glycogen synthase kinase 3 alpha [Source:HGNC Symbol;Acc:HGNC:4616] 0.11 2.46E-02 
SIRT1 sirtuin 1 [Source:HGNC Symbol;Acc:HGNC:14929] 0.15 2.92E-02 
SREBF1 sterol regulatory element binding transcription factor 1 [Source:HGNC Symbol;Acc:HGNC:11289] 0.09 3.52E-02 
 
